<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">89068</article-id><article-id pub-id-type="doi">10.7554/eLife.89068</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.89068.2</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Polymorphisms in intron 1 of HLA-DRA differentially associate with type 1 diabetes and celiac disease and implicate involvement of complement system genes C4A and C4B</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Aydemir</surname><given-names>Ozkan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3458-6527</contrib-id><email>ozkanaydemir@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bailey</surname><given-names>Jeffrey A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6899-8204</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Agardh</surname><given-names>Daniel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1435-1234</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lernmark</surname><given-names>Åke</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1735-0499</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Noble</surname><given-names>Janelle A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0002-5529-1186</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Andersson Svärd</surname><given-names>Agnes</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6838-7382</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Blankenhorn</surname><given-names>Elizabeth P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6331-0319</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Parikh</surname><given-names>Hemang M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9076-6709</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ziegler</surname><given-names>Anette-G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6290-5548</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Toppari</surname><given-names>Jorma</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Akolkar</surname><given-names>Beena</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hagopian</surname><given-names>William A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2979-0475</contrib-id><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rewers</surname><given-names>Marian J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3829-9207</contrib-id><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mordes</surname><given-names>John P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2414-380X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>TEDDY Study Group</collab><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund18"/><xref ref-type="other" rid="fund19"/><xref ref-type="other" rid="fund20"/><xref ref-type="other" rid="fund21"/><xref ref-type="other" rid="fund22"/><xref ref-type="other" rid="fund23"/><xref ref-type="other" rid="fund24"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Chan Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Department of Pathology and Laboratory Medicine and Center for Computational Molecular Biology, Brown University</institution></institution-wrap><addr-line><named-content content-type="city">Providence</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02z31g829</institution-id><institution>Department of Clinical Sciences, Lund University CRC Skane University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Malmö</named-content></addr-line><country>Sweden</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04bdffz58</institution-id><institution>Drexel University College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032db5x82</institution-id><institution>Health Informatics Institute, Morsani College of Medicine, University of South Florida</institution></institution-wrap><addr-line><named-content content-type="city">Tampa</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02kkvpp62</institution-id><institution>Institute of Diabetes Research, Helmholtz Zentrum München, Klinikum rechts der Isar, Technische Universität München, and Forschergruppe Diabetes e.V.</institution></institution-wrap><addr-line><named-content content-type="city">Neuherberg</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vghhr25</institution-id><institution>Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, and Centre for Population Health Research, University of Turku</institution></institution-wrap><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dbzj528</institution-id><institution>Department of Pediatrics, Turku University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Turku</named-content></addr-line><country>Finland</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ets8c94</institution-id><institution>Pediatrics, Indiana University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Department of Medicine, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>Barbara Davis Center for Childhood Diabetes, University of Colorado</institution></institution-wrap><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>The University of Melbourne</institution></institution-wrap><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>The University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>02</month><year>2026</year></pub-date><volume>12</volume><elocation-id>RP89068</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-05-15"><day>15</day><month>05</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-06-20"><day>20</day><month>06</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.06.12.23291280"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-09-01"><day>01</day><month>09</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.89068.1"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-89068-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-89068-figures-v1.pdf"/><abstract><p>Polymorphisms in genes in the human leukocyte antigen (HLA) class II region comprise the most important inherited risk factors for many autoimmune diseases, including type 1 diabetes (T1D) and celiac disease (CD): both diseases are positively associated with the HLA-DR3 haplotype (<italic>DRB1*03:01-DQA1*05:01-DQB1*02:01</italic>). Studies of two different populations have recently documented that T1D susceptibility in HLA-DR3 homozygous individuals is stratified by a haplotype consisting of three single nucleotide polymorphisms (‘tri-SNP’) in intron 1 of the <italic>HLA-DRA</italic> gene. In this study, we use a large cohort from the longitudinal ‘The Environmental Determinants of Diabetes in the Young’ (TEDDY) study to further refine the tri-SNP association with T1D and with autoantibody-defined T1D endotypes. We found that the tri-SNP association is primarily in subjects whose first-appearing T1D autoantibody is to insulin. In addition, we discovered that the tri-SNP is also associated with CD, and that the particular tri-SNP haplotype (‘101’) that is negatively associated with T1D risk is positively associated with risk for CD. The opposite effect of the tri-SNP haplotype on two DR3-associated diseases can enhance and refine current models of disease prediction based on genetic risk. Finally, we investigated possible functional differences between the individuals carrying high and low-risk tri-SNP haplotypes and found that differences in complement system genes C4A and C4B may underlie the observed divergence in disease risk.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>T1D</kwd><kwd>diabetes</kwd><kwd>celiac disease</kwd><kwd>complement</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK63861</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043z4tv69</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04byxyr05</institution-id><institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution></institution-wrap></funding-source><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j4k1h63</institution-id><institution>National Institute of Environmental Health Sciences</institution></institution-wrap></funding-source><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK63829</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK63821</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK63865</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK63863</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK63836</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK63790</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK63829</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK63861</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK63821</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK63865</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK63863</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK63836</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK95300</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK100238</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK106955</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund20"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK117483</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund21"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>UC4 DK112243</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund22"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK124166</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund23"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>U01 DK128847</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><award-group id="fund24"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>HHSN267200700014C</award-id><principal-award-recipient><institution>TEDDY Study Group</institution></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>HLA-DRA intronic haplotype associates with opposite effects on type 1 diabetes and celiac disease, refining genetic risk prediction and implicating complement genes C4A and C4B in divergent autoimmune pathways.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Type 1 diabetes (T1D) is an autoimmune disease that results from the destruction of pancreatic islet β cells by autoreactive T cells (<xref ref-type="bibr" rid="bib56">Wang et al., 2017</xref>). Clinical onset is preceded by a prodrome of β-cell autoimmunity, usually marked by the appearance of autoantibodies directed principally at insulin (IAA), glutamic acid decarboxylase (GADA), and islet antigen-2 (IA-2A). T1D is a non-Mendelian polygenic disorder involving the interaction of multiple gene variants, environmental factors, and immunoregulatory dysfunction (<xref ref-type="bibr" rid="bib56">Wang et al., 2017</xref>). Only about 12% of persons with T1D have a first-degree relative (FDR) with the disease, a percentage that has remained unchanged despite increasing incidence (<xref ref-type="bibr" rid="bib12">Dahlquist et al., 1989</xref>; <xref ref-type="bibr" rid="bib36">Parkkola et al., 2013</xref>). The environmental factors that may precipitate disease in genetically susceptible individuals and the mechanisms by which they act have not been completely identified.</p><p>Gluten enteropathy, or CD, is also an autoimmune disorder. It results in atrophy of intestinal villi in the context of intestinal T cell inflammation and is associated with the presence of transglutaminase autoantibodies (tTGA) (<xref ref-type="bibr" rid="bib24">Husby et al., 2012</xref>; <xref ref-type="bibr" rid="bib29">Leonard et al., 2017</xref>). Although gluten is necessary for the disease, it is not by itself sufficient, and CD is likely triggered by other environmental exposures (<xref ref-type="bibr" rid="bib1">Andrén Aronsson et al., 2019</xref>). Clinical disease is characterized by a range of symptoms and signs, including abdominal discomfort, disordered intestinal motility, and nutrient malabsorption. Like T1D, CD is a non-Mendelian polygenic disorder involving the interaction of multiple gene variants, environmental factors, and immunoregulatory dysfunction. On average, about 7.5% of persons with CD have a first-degree relative with the disorder, but the prevalence varies with the relationship, sex, and geographic location (<xref ref-type="bibr" rid="bib48">Singh et al., 2015</xref>).</p><p>The major genetic loci for both T1D and CD susceptibility encode major histocompatibility complex (MHC) class II cell surface antigens; they are encoded by the HLA complex genes on chromosome 6 (<xref ref-type="bibr" rid="bib20">Gutierrez-Arcelus et al., 2016</xref>). Together with the T cell receptor (TCR) and an autoantigenic peptide, these glycoproteins form the ‘tri-molecular complex’ that is central to cell-mediated immune and autoimmune responses.</p><p>T1D susceptibility is most strongly associated with polymorphisms in HLA class II genes. The major HLA class II genes that predispose to T1D are <italic>HLA-DRB1, DQA1,</italic> and <italic>DQB1,</italic> which encode the HLA DR and DQ heterodimers (<xref ref-type="bibr" rid="bib40">Polychronakos and Li, 2011</xref>). Most T1D patients bear genetic haplotypes known as HLA-DR3 (<italic>DRB1*03:01-DQA1*05:01-DQB1*02:01</italic>) and HLA-DR4 (<italic>DRB1*04:01-, *04:02-, *04:04-,</italic> or <italic>*04:05-DQA1*03:01-DQB1*03:02</italic>). The DR3 haplotype can also be abbreviated as DR3-DQ2, with DR3 referring to the presence of the <italic>DRB1*03:01</italic> gene and DQ2 referring to the heterodimeric protein product of the <italic>DQA1*05:01</italic> and <italic>DQB1*02:01</italic> genes. The DR4 haplotype represents any of the <italic>DRB1*04</italic>-encoded allotypes with DQ8<italic>,</italic> the heterodimeric protein product of the <italic>HLA-DQA1*03:01</italic> and <italic>DQB1*03:02</italic> genes (DR4-DQ8). T1D is also associated with HLA class I genes (<xref ref-type="bibr" rid="bib34">Noble et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Polychronakos and Li, 2011</xref>) and with class II <italic>HLA-DPB1</italic> genes (<xref ref-type="bibr" rid="bib10">Bradfield et al., 2011</xref>). Genome-wide association studies (GWAS) revealed &gt;50 non-MHC loci associated with the disease (<xref ref-type="bibr" rid="bib10">Bradfield et al., 2011</xref>) and more recent analyses have extended that number to &gt;75 (<xref ref-type="bibr" rid="bib44">Robertson et al., 2021</xref>). Because their individual contribution to total risk is small (<xref ref-type="bibr" rid="bib5">Baranzini, 2009</xref>), the analysis of non-MHC risk loci has not improved our ability to predict disease based on genotype alone.</p><p>In CD, about 90% of patients carry DR3-DQ2, and most of the remaining CD patients carry the DR4-DQ8 haplotype (<xref ref-type="bibr" rid="bib11">Brown et al., 2019</xref>). Fine mapping of the HLA region in persons with CD has identified additional associations that account for approximately 18% of the genetic risk (<xref ref-type="bibr" rid="bib19">Gutierrez-Achury et al., 2015</xref>). These loci, together with the &gt;50 known non-MHC susceptibility loci identified by GWAS, are thought to explain up to 48% of overall CD heritability (<xref ref-type="bibr" rid="bib19">Gutierrez-Achury et al., 2015</xref>).</p><p>The DQ2 and DQ8 haplotypes, positively associated with CD, are carried on the DR3-DQ2 and DR4-DQ8 haplotypes, respectively, that are predisposing for T1D. The occasional presence of both T1D and CD in the same individual is, therefore, not surprising. The rate at which CD occurs in persons with T1D varies substantially among various populations and reportedly ranges from 2.5 to 16.4% (<xref ref-type="bibr" rid="bib15">De Vitis et al., 1996</xref>; <xref ref-type="bibr" rid="bib49">Szaflarska-Popławska, 2014</xref>). In the HLA-selected TEDDY study, T1D autoimmunity usually preceded CD autoimmunity in cases that had both (<xref ref-type="bibr" rid="bib22">Hagopian et al., 2017</xref>).</p><p>In the case of T1D, HLA genotyping can identify persons at risk for the disease, but only about 1 in 15 (∼7%) individuals with even the highest-risk HLA genotype identified in Europeans (HLA-DR3/DR4 heterozygotes) develop the disorder (<xref ref-type="bibr" rid="bib41">Rewers et al., 1996</xref>). Similarly, only about 3% of persons with DQ2 or DQ8 develop celiac disease (<xref ref-type="bibr" rid="bib11">Brown et al., 2019</xref>). Recent studies that coupled genetic analysis with phenotypic markers have improved our ability to predict islet autoantibodies and T1D in the general population (<xref ref-type="bibr" rid="bib9">Bonifacio et al., 2018</xref>), but additional genetic risk remains to be discovered (<xref ref-type="bibr" rid="bib39">Pierce et al., 2013</xref>). Understanding of the detailed genetic risk conferred by HLA-DR and -DQ-encoding genes remains incomplete and provided the impetus for these studies.</p><p>We have previously reported that susceptibility to T1D among persons homozygous for the high-risk DR3-DQ2 haplotype is powerfully modulated by variation within intron-1 of the <italic>HLA-DRA</italic> gene (<xref ref-type="bibr" rid="bib2">Aydemir et al., 2019</xref>), a gene that, unlike most HLA-encoding genes, is considered essentially invariant and largely ignored in HLA association studies. This variation comprises three single-nucleotide polymorphisms (SNPs): rs3135394, rs9268645, and rs3129877 (referred to here as the ‘tri-SNP’) in a 100 bp interval within intron 1. We called the T1D risk haplotype (nucleotides AGG) ‘010’ using (0) to designate the reference and (1) alternate alleles, respectively. T1D protection was conferred by the ‘101’ haplotype (GCA). The effect of the tri-SNP on T1D susceptibility was discovered in an analysis of samples drawn from the Type 1 Diabetes Genetics Consortium (T1DGC), the Swedish Better Diabetes Diagnosis (BDD) study, and the Swedish Diabetes Prediction in Skåne (DiPiS) study (<xref ref-type="bibr" rid="bib2">Aydemir et al., 2019</xref>). The relative T1D risk of the 010/010 genotype, compared to the homozygous 101/101 genotype, was substantial in both the T1DGC and Swedish DR3/3 cohorts (odds ratio 4.65, <italic>p</italic>=1.69 × 10<sup>–13</sup>). This association was later independently replicated in a separate cohort of DR3-DQ2/DR3-DQ2 individuals from Finland (<xref ref-type="bibr" rid="bib35">Nygård et al., 2021</xref>). These investigators reported that the 010/010 (AGG/AGG) or 010 /x (AGG/x) tri-SNP haplotypes were significantly more common in patients with T1D (OR = 1.70, CI 95%=1.15–2.51, <italic>p</italic>=0.007) than in non-diabetic controls.</p><p>Here, we report an expanded analysis of the effect of the tri-SNP on the appearance of islet autoimmunity and the subsequent progression to T1D using data from the large population enrolled in TEDDY study (<xref ref-type="bibr" rid="bib51">TEDDY Study Group, 2008</xref>). In addition, because CD is also documented in the TEDDY study, the novel and unexpected discovery was made that the tri-SNP 101 genotype that confers T1D protection was associated with increased susceptibility to CD.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Study population demographics</title><p>The TEDDY database analyzed here was frozen as of 31 October 2021 and the present analysis represents a median follow-up of 12.7 years (IQR = 10.9–14.4). 382 (5.0%) children had been diagnosed with T1D and 617 (8.0%) with CD. The TEDDY study is ongoing and about 75% of the research subjects have still to age out (15 years of age) of the study.</p><p>There were 7759 study subjects with HLA and tri-SNP typing data available. Ancestry distribution was 89.6% European (EUR, N=6953), 9.1% Ad Mixed American (AMR, N=707), 1% African (AFR, N=82), 0.2% South Asian (SAS, N=14), and &lt;0.1% East Asian (EAS, N=3).</p><p>The distribution of tri-SNP haplotypes and HLA genotypes is shown in <xref ref-type="table" rid="table1">Table 1</xref>. As anticipated, given the study inclusion criteria, most (N=7503) participants were homozygous for either DR3 or DR4, heterozygous for DR3/DR4, or heterozygous for DR4/DR8. With respect to the distribution of tri-SNP haplotypes in this population, nearly all subjects had at least one 101 or 010 tri-SNP; only 22 (0.3%) did not. The 101 tri-SNP haplotype was observed almost exclusively coupled to the DR3-DQ2 haplotype; 99.6% (2357/2366) of the chromosomes from 101/101 homozygous individuals carried the DR3-DQ2 haplotype. Similarly, 101 is highly enriched in the DR3 population; 84% (2716/3232) of the chromosomes from DR3 homozygous individuals had 101, in line with our previous report (<xref ref-type="bibr" rid="bib2">Aydemir et al., 2019</xref>). Approximately 99% of the DR3 homozygous population carried either 010 or 101 (3203/3232). We also observed that 98.2% of the DR4/DR4 homozygous population carried 010 (3007/3062).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Distribution of human leukocyte antigen (HLA) and Tri-single-nucleotide polymorphism (SNP) haplotypes among The Environmental Determinants of Diabetes in the Young (TEDDY) samples.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="12">Tri-SNP Genotype</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>010/010</bold></td><td align="left" valign="bottom"><bold>010/101</bold></td><td align="left" valign="bottom"><bold>101/101</bold></td><td align="left" valign="bottom"><bold>000/010</bold></td><td align="left" valign="bottom"><bold>001/010</bold></td><td align="left" valign="bottom"><bold>000/101</bold></td><td align="left" valign="bottom"><bold>000/000</bold></td><td align="left" valign="bottom"><bold>000/001</bold></td><td align="left" valign="bottom"><bold>001/101</bold></td><td align="left" valign="bottom"><bold>011/101</bold></td><td align="left" valign="bottom"><bold>010/011</bold></td><td align="left" valign="bottom"><bold>All</bold></td></tr><tr><td align="left" valign="bottom"><bold>HLA</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>DR3/DR3</bold></td><td align="left" valign="bottom">62</td><td align="left" valign="bottom">348</td><td align="left" valign="bottom">1177</td><td align="left" valign="bottom">13</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">11</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">1616 (20.8%)</td></tr><tr><td align="left" valign="bottom"><bold>DR3/DR4</bold></td><td align="left" valign="bottom">408</td><td align="left" valign="bottom">2550</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">19</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">30</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">3022 (38.9%)</td></tr><tr><td align="left" valign="bottom"><bold>DR4/DR4</bold></td><td align="left" valign="bottom">1480</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">39</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">1531 (19.7%)</td></tr><tr><td align="left" valign="bottom"><bold>DR4/DR8</bold></td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">1297</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">17</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">1334 (17.2%)</td></tr><tr><td align="left" valign="bottom"><bold>DR1/DR4</bold></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">15</td><td align="left" valign="bottom">143</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">160 (2.1%)</td></tr><tr><td align="left" valign="bottom"><bold>DR4/DR13</bold></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">56</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">57 (0.7%)</td></tr><tr><td align="left" valign="bottom"><bold>DR3/DR9</bold></td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">16</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">18 (0.2%)</td></tr><tr><td align="left" valign="bottom"><bold>DR4/DR9</bold></td><td align="left" valign="bottom">13</td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">14 (0.2%)</td></tr><tr><td align="left" valign="bottom"><bold>DR4/DR4*030 X/020</bold> X</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">4 (0.1%)</td></tr><tr><td align="left" valign="bottom"><bold>DR4/DR4*030 X/0304</bold></td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">3 (0.0%)</td></tr><tr><td align="left" valign="bottom"><bold>All</bold></td><td align="left" valign="bottom">1986<break/>(25.6%)</td><td align="left" valign="bottom">2920<break/>(37.6%)</td><td align="left" valign="bottom">1183<break/>(15.2%)</td><td align="left" valign="bottom">1383<break/>(17.8%)</td><td align="left" valign="bottom">217<break/>(2.8%)</td><td align="left" valign="bottom">42<break/>(0.5%)</td><td align="left" valign="bottom">17<break/>(0.2%)</td><td align="left" valign="bottom">5<break/>(0.1%)</td><td align="left" valign="bottom">3<break/>(0.0%)</td><td align="left" valign="bottom">2<break/>(0.0%)</td><td align="left" valign="bottom">1<break/>(0.0%)</td><td align="left" valign="bottom">7759 (100%)</td></tr></tbody></table></table-wrap><p>Cox PH analysis requires each level of the categorical variables to have at least one event and one non-event data point. We removed the samples that belonged to categories with too few individuals (&lt;20) to accommodate this requirement. These included samples from: HLA classes DR3/DR9 (n=18), DR4/DR9 (n=14), DR4/DR4*030 X/020 X (n=4), DR4/DR4*030 X/0304 (n=3); populations SAS (n=14) and EAS (n=4). 7703 samples remained in the final set. Descriptive characteristics of the final data set with respect to each outcome studied are provided in <xref ref-type="table" rid="table2 table3 table4 table5 table6 table7">Tables 2–7</xref>.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Descriptive characteristics of children with respect to the islet autoimmunity (IA) outcome in number (percentage).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">IA</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>No</bold></td><td align="left" valign="bottom"><bold>Yes</bold></td><td align="left" valign="bottom"><bold>All</bold></td></tr><tr><td align="left" valign="bottom"><bold>Sex</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Female</td><td align="left" valign="bottom">3388 (49.5)</td><td align="left" valign="bottom">390 (45.5)</td><td align="left" valign="bottom">3778 (49.0)</td></tr><tr><td align="left" valign="bottom"> Male</td><td align="left" valign="bottom">3457 (50.5)</td><td align="left" valign="bottom">468 (54.5)</td><td align="left" valign="bottom">3925 (51.0)</td></tr><tr><td align="left" valign="bottom"><bold>POP</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> EUR</td><td align="left" valign="bottom">6122 (89.4)</td><td align="left" valign="bottom">796 (92.8)</td><td align="left" valign="bottom">6918 (89.8)</td></tr><tr><td align="left" valign="bottom"> AMR</td><td align="left" valign="bottom">647 (9.5)</td><td align="left" valign="bottom">56 (6.5)</td><td align="left" valign="bottom">703 (9.1)</td></tr><tr><td align="left" valign="bottom"> AFR</td><td align="left" valign="bottom">76 (1.1)</td><td align="left" valign="bottom">6 (0.7)</td><td align="left" valign="bottom">82 (1.1)</td></tr><tr><td align="left" valign="bottom"><bold>HLA Type</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> DR1/DR4</td><td align="left" valign="bottom">142 (2.1)</td><td align="left" valign="bottom">18 (2.1)</td><td align="left" valign="bottom">160 (2.1)</td></tr><tr><td align="left" valign="bottom"> DR3/DR3</td><td align="left" valign="bottom">1486 (21.7)</td><td align="left" valign="bottom">121 (14.1)</td><td align="left" valign="bottom">1607 (20.9)</td></tr><tr><td align="left" valign="bottom"> DR3/DR4</td><td align="left" valign="bottom">2599 (38.0)</td><td align="left" valign="bottom">418 (48.7)</td><td align="left" valign="bottom">3017 (39.2)</td></tr><tr><td align="left" valign="bottom"> DR4/DR13</td><td align="left" valign="bottom">47 (0.7)</td><td align="left" valign="bottom">10 (1.2)</td><td align="left" valign="bottom">57 (0.7)</td></tr><tr><td align="left" valign="bottom"> DR4/DR4</td><td align="left" valign="bottom">1371 (20.0)</td><td align="left" valign="bottom">158 (18.4)</td><td align="left" valign="bottom">1529 (19.8)</td></tr><tr><td align="left" valign="bottom"> DR4/DR8</td><td align="left" valign="bottom">1200 (17.5)</td><td align="left" valign="bottom">133 (15.5)</td><td align="left" valign="bottom">1333 (17.3)</td></tr><tr><td align="left" valign="bottom"><bold>Country</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> US</td><td align="left" valign="bottom">2885 (42.1)</td><td align="left" valign="bottom">297 (34.6)</td><td align="left" valign="bottom">3182 (41.3)</td></tr><tr><td align="left" valign="bottom"> SWE</td><td align="left" valign="bottom">2019 (29.5)</td><td align="left" valign="bottom">290 (33.8)</td><td align="left" valign="bottom">2309 (30.0)</td></tr><tr><td align="left" valign="bottom"> FIN</td><td align="left" valign="bottom">1482 (21.7)</td><td align="left" valign="bottom">214 (24.9)</td><td align="left" valign="bottom">1696 (22.0)</td></tr><tr><td align="left" valign="bottom"> GER</td><td align="left" valign="bottom">459 (6.7)</td><td align="left" valign="bottom">57 (6.6)</td><td align="left" valign="bottom">516 (6.7)</td></tr><tr><td align="left" valign="bottom"><bold>FDR</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> 0</td><td align="left" valign="bottom">6155 (89.9)</td><td align="left" valign="bottom">691 (80.5)</td><td align="left" valign="bottom">6846 (88.9)</td></tr><tr><td align="left" valign="bottom"> 1</td><td align="left" valign="bottom">690 (10.1)</td><td align="left" valign="bottom">167 (19.5)</td><td align="left" valign="bottom">857 (11.1)</td></tr><tr><td align="left" valign="bottom"><bold>All</bold></td><td align="left" valign="bottom">6845 (88.9)</td><td align="left" valign="bottom">858 (11.1)</td><td align="left" valign="bottom">7703 (100)</td></tr></tbody></table></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Descriptive characteristics of children with respect to type 1 diabetes diagnosis (T1D) outcome in number (percentage).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">T1D</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>Sex</bold></td><td align="left" valign="top"><bold>No</bold></td><td align="left" valign="top"><bold>Yes</bold></td><td align="left" valign="top"><bold>All</bold></td></tr><tr><td align="left" valign="top"> Female</td><td align="left" valign="top">3597 (49.2)</td><td align="left" valign="top">181 (45.6)</td><td align="left" valign="top">3778 (49.0)</td></tr><tr><td align="left" valign="top"> Male</td><td align="left" valign="top">3709 (50.8)</td><td align="left" valign="top">216 (54.4)</td><td align="left" valign="top">3925 (51.0)</td></tr><tr><td align="left" valign="top"><bold>POP</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> EUR</td><td align="left" valign="top">6552 (89.7)</td><td align="left" valign="top">366 (92.2)</td><td align="left" valign="top">6918 (89.8)</td></tr><tr><td align="left" valign="top"> AMR</td><td align="left" valign="top">674 (9.2)</td><td align="left" valign="top">29 (7.3)</td><td align="left" valign="top">703 (9.1)</td></tr><tr><td align="left" valign="top"> AFR</td><td align="left" valign="top">80 (1.1)</td><td align="left" valign="top">2 (0.5)</td><td align="left" valign="top">82 (1.1)</td></tr><tr><td align="left" valign="top"><bold>HLA Type</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> DR1/DR4</td><td align="left" valign="top">146 (2.0)</td><td align="left" valign="top">14 (3.5)</td><td align="left" valign="top">160 (2.1)</td></tr><tr><td align="left" valign="top"> DR3/DR3</td><td align="left" valign="top">1571 (21.5)</td><td align="left" valign="top">36 (9.1)</td><td align="left" valign="top">1607 (20.9)</td></tr><tr><td align="left" valign="top"> DR3/DR4</td><td align="left" valign="top">2797 (38.3)</td><td align="left" valign="top">220 (55.4)</td><td align="left" valign="top">3017 (39.2)</td></tr><tr><td align="left" valign="top"> DR4/DR13</td><td align="left" valign="top">51 (0.7)</td><td align="left" valign="top">6 (1.5)</td><td align="left" valign="top">57 (0.7)</td></tr><tr><td align="left" valign="top"> DR4/DR4</td><td align="left" valign="top">1457 (19.9)</td><td align="left" valign="top">72 (18.1)</td><td align="left" valign="top">1529 (19.8)</td></tr><tr><td align="left" valign="top"> DR4/DR8</td><td align="left" valign="top">1284 (17.6)</td><td align="left" valign="top">49 (12.3)</td><td align="left" valign="top">1333 (17.3)</td></tr><tr><td align="left" valign="top"><bold>Country</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> US</td><td align="left" valign="top">3034 (41.5)</td><td align="left" valign="top">148 (37.3)</td><td align="left" valign="top">3182 (41.3)</td></tr><tr><td align="left" valign="top"> SWE</td><td align="left" valign="top">2204 (30.2)</td><td align="left" valign="top">105 (26.4)</td><td align="left" valign="top">2309 (30.0)</td></tr><tr><td align="left" valign="top"> FIN</td><td align="left" valign="top">1591 (21.8)</td><td align="left" valign="top">105 (26.4)</td><td align="left" valign="top">1696 (22.0)</td></tr><tr><td align="left" valign="top"> GER</td><td align="left" valign="top">477 (6.5)</td><td align="left" valign="top">39 (9.8)</td><td align="left" valign="top">516 (6.7)</td></tr><tr><td align="left" valign="top"><bold>FDR</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> 0</td><td align="left" valign="top">6560 (89.8)</td><td align="left" valign="top">286 (72.0)</td><td align="left" valign="top">6846 (88.9)</td></tr><tr><td align="left" valign="top"> 1</td><td align="left" valign="top">746 (10.2)</td><td align="left" valign="top">111 (28.0)</td><td align="left" valign="top">857 (11.1)</td></tr><tr><td align="left" valign="top"><bold>All</bold></td><td align="left" valign="top">7306 (94.8)</td><td align="left" valign="top">397 (5.2)</td><td align="left" valign="top">7703 (100)</td></tr></tbody></table></table-wrap><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Descriptive characteristics of children with respect to glutamic acid decarboxylase autoantibody (GADA)-first appearing antibody outcome in number (percentage).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">GADA first</th></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>No</bold></td><td align="left" valign="top"><bold>Yes</bold></td><td align="left" valign="top"><bold>All</bold></td></tr><tr><td align="left" valign="top"><bold>Sex</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> Female</td><td align="left" valign="top">3601 (49.2)</td><td align="left" valign="top">177 (46.3)</td><td align="left" valign="top">3778 (49.0)</td></tr><tr><td align="left" valign="top"> Male</td><td align="left" valign="top">3720 (50.8)</td><td align="left" valign="top">205 (53.7)</td><td align="left" valign="top">3925 (51.0)</td></tr><tr><td align="left" valign="top"><bold>POP</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> EUR</td><td align="left" valign="top">6565 (89.7)</td><td align="left" valign="top">353 (92.4)</td><td align="left" valign="top">6918 (89.8)</td></tr><tr><td align="left" valign="top"> AMR</td><td align="left" valign="top">678 (9.3)</td><td align="left" valign="top">25 (6.5)</td><td align="left" valign="top">703 (9.1)</td></tr><tr><td align="left" valign="top"> AFR</td><td align="left" valign="top">78 (1.1)</td><td align="left" valign="top">4 (1.0)</td><td align="left" valign="top">82 (1.1)</td></tr><tr><td align="left" valign="top"><bold>HLA Type</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> DR1/DR4</td><td align="left" valign="top">157 (2.1)</td><td align="left" valign="top">3 (0.8)</td><td align="left" valign="top">160 (2.1)</td></tr><tr><td align="left" valign="top"> DR3/DR3</td><td align="left" valign="top">1522 (20.8)</td><td align="left" valign="top">85 (22.3)</td><td align="left" valign="top">1607 (20.9)</td></tr><tr><td align="left" valign="top"> DR3/DR4</td><td align="left" valign="top">2828 (38.6)</td><td align="left" valign="top">189 (49.5)</td><td align="left" valign="top">3017 (39.2)</td></tr><tr><td align="left" valign="top"> DR4/DR13</td><td align="left" valign="top">55 (0.8)</td><td align="left" valign="top">2 (0.5)</td><td align="left" valign="top">57 (0.7)</td></tr><tr><td align="left" valign="top"> DR4/DR4</td><td align="left" valign="top">1472 (20.1)</td><td align="left" valign="top">57 (14.9)</td><td align="left" valign="top">1529 (19.8)</td></tr><tr><td align="left" valign="top"> DR4/DR8</td><td align="left" valign="top">1287 (17.6)</td><td align="left" valign="top">46 (12.0)</td><td align="left" valign="top">1333 (17.3)</td></tr><tr><td align="left" valign="top"><bold>Country</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> US</td><td align="left" valign="top">3036 (41.5)</td><td align="left" valign="top">146 (38.2)</td><td align="left" valign="top">3182 (41.3)</td></tr><tr><td align="left" valign="top"> SWE</td><td align="left" valign="top">2164 (29.6)</td><td align="left" valign="top">145 (38.0)</td><td align="left" valign="top">2309 (30.0)</td></tr><tr><td align="left" valign="top"> FIN</td><td align="left" valign="top">1622 (22.2)</td><td align="left" valign="top">74 (19.4)</td><td align="left" valign="top">1696 (22.0)</td></tr><tr><td align="left" valign="top"> GER</td><td align="left" valign="top">499 (6.8)</td><td align="left" valign="top">17 (4.5)</td><td align="left" valign="top">516 (6.7)</td></tr><tr><td align="left" valign="top"><bold>FDR</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"> No</td><td align="left" valign="top">6531 (89.2)</td><td align="left" valign="top">315 (82.5)</td><td align="left" valign="top">6846 (88.9)</td></tr><tr><td align="left" valign="top"> Yes</td><td align="left" valign="top">790 (10.8)</td><td align="left" valign="top">67 (17.5)</td><td align="left" valign="top">857 (11.1)</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><bold>All</bold></td><td align="left" valign="top">7321 (95.0)</td><td align="left" valign="top">382 (5.0)</td><td align="left" valign="top">7703 (100)</td></tr></tbody></table></table-wrap><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Descriptive characteristics of children with respect to insulin autoantibody (IAA)-first appearing antibody outcome in number (percentage).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">IAA first</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>No</bold></td><td align="left" valign="bottom"><bold>Yes</bold></td><td align="left" valign="bottom"><bold>All</bold></td></tr><tr><td align="left" valign="bottom"><bold>Sex</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Female</td><td align="left" valign="bottom">3636 (49.2)</td><td align="left" valign="bottom">142 (45.4)</td><td align="left" valign="bottom">3778 (49.0)</td></tr><tr><td align="left" valign="bottom"> Male</td><td align="left" valign="bottom">3754 (50.8)</td><td align="left" valign="bottom">171 (54.6)</td><td align="left" valign="bottom">3925 (51.0)</td></tr><tr><td align="left" valign="bottom"><bold>POP</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> EUR</td><td align="left" valign="bottom">6624 (89.6)</td><td align="left" valign="bottom">294 (93.9)</td><td align="left" valign="bottom">6918 (89.8)</td></tr><tr><td align="left" valign="bottom"> AMR</td><td align="left" valign="bottom">685 (9.3)</td><td align="left" valign="bottom">18 (5.8)</td><td align="left" valign="bottom">703 (9.1)</td></tr><tr><td align="left" valign="bottom"> AFR</td><td align="left" valign="bottom">81 (1.1)</td><td align="left" valign="bottom">1 (0.3)</td><td align="left" valign="bottom">82 (1.1)</td></tr><tr><td align="left" valign="bottom"><bold>HLA Type</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> DR1/DR4</td><td align="left" valign="bottom">151 (2.0)</td><td align="left" valign="bottom">9 (2.9)</td><td align="left" valign="bottom">160 (2.1)</td></tr><tr><td align="left" valign="bottom"> DR3/DR3</td><td align="left" valign="bottom">1578 (21.4)</td><td align="left" valign="bottom">29 (9.3)</td><td align="left" valign="bottom">1607 (20.9)</td></tr><tr><td align="left" valign="bottom"> DR3/DR4</td><td align="left" valign="bottom">2870 (38.8)</td><td align="left" valign="bottom">147 (47.0)</td><td align="left" valign="bottom">3017 (39.2)</td></tr><tr><td align="left" valign="bottom"> DR4/DR13</td><td align="left" valign="bottom">52 (0.7)</td><td align="left" valign="bottom">5 (1.6)</td><td align="left" valign="bottom">57 (0.7)</td></tr><tr><td align="left" valign="bottom"> DR4/DR4</td><td align="left" valign="bottom">1471 (19.9)</td><td align="left" valign="bottom">58 (18.5)</td><td align="left" valign="bottom">1529 (19.8)</td></tr><tr><td align="left" valign="bottom"> DR4/DR8</td><td align="left" valign="bottom">1268 (17.2)</td><td align="left" valign="bottom">65 (20.8)</td><td align="left" valign="bottom">1333 (17.3)</td></tr><tr><td align="left" valign="bottom"><bold>Country</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> US</td><td align="left" valign="bottom">3082 (41.7)</td><td align="left" valign="bottom">100 (31.9)</td><td align="left" valign="bottom">3182 (41.3)</td></tr><tr><td align="left" valign="bottom"> SWE</td><td align="left" valign="bottom">2215 (30.0)</td><td align="left" valign="bottom">94 (30.0)</td><td align="left" valign="bottom">2309 (30.0)</td></tr><tr><td align="left" valign="bottom"> FIN</td><td align="left" valign="bottom">1597 (21.6)</td><td align="left" valign="bottom">99 (31.6)</td><td align="left" valign="bottom">1696 (22.0)</td></tr><tr><td align="left" valign="bottom"> GER</td><td align="left" valign="bottom">496 (6.7)</td><td align="left" valign="bottom">20 (6.4)</td><td align="left" valign="bottom">516 (6.7)</td></tr><tr><td align="left" valign="bottom"><bold>FDR</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> No</td><td align="left" valign="bottom">6600 (89.3)</td><td align="left" valign="bottom">246 (78.6)</td><td align="left" valign="bottom">6846 (88.9)</td></tr><tr><td align="left" valign="bottom"> Yes</td><td align="left" valign="bottom">790 (10.7)</td><td align="left" valign="bottom">67 (21.4)</td><td align="left" valign="bottom">857 (11.1)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>All</bold></td><td align="left" valign="bottom">7390 (95.9)</td><td align="left" valign="bottom">313 (4.1)</td><td align="left" valign="bottom">7703 (100)</td></tr></tbody></table></table-wrap><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>Descriptive characteristics of children with respect to celiac disease diagnosis (CD) outcome in number (percentage).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">CD</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>No</bold></td><td align="left" valign="bottom"><bold>Yes</bold></td><td align="left" valign="bottom"><bold>All</bold></td></tr><tr><td align="left" valign="bottom"><bold>Sex</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Female</td><td align="left" valign="bottom">3413 (48.2)</td><td align="left" valign="bottom">365 (59.2)</td><td align="left" valign="bottom">3778 (49.0)</td></tr><tr><td align="left" valign="bottom"> Male</td><td align="left" valign="bottom">3673 (51.8)</td><td align="left" valign="bottom">252 (40.8)</td><td align="left" valign="bottom">3925 (51.0)</td></tr><tr><td align="left" valign="bottom"><bold>POP</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> EUR</td><td align="left" valign="bottom">6325 (89.3)</td><td align="left" valign="bottom">593 (96.1)</td><td align="left" valign="bottom">6918 (89.8)</td></tr><tr><td align="left" valign="bottom"> AMR</td><td align="left" valign="bottom">681 (9.6)</td><td align="left" valign="bottom">22 (3.6)</td><td align="left" valign="bottom">703 (9.1)</td></tr><tr><td align="left" valign="bottom"> AFR</td><td align="left" valign="bottom">80 (1.1)</td><td align="left" valign="bottom">2 (0.3)</td><td align="left" valign="bottom">82 (1.1)</td></tr><tr><td align="left" valign="bottom"><bold>HLA Type</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> DR1/DR4</td><td align="left" valign="bottom">155 (2.2)</td><td align="left" valign="bottom">5 (0.8)</td><td align="left" valign="bottom">160 (2.1)</td></tr><tr><td align="left" valign="bottom"> DR3/DR3</td><td align="left" valign="bottom">1308 (18.5)</td><td align="left" valign="bottom">299 (48.5)</td><td align="left" valign="bottom">1607 (20.9)</td></tr><tr><td align="left" valign="bottom"> DR3/DR4</td><td align="left" valign="bottom">2805 (39.6)</td><td align="left" valign="bottom">212 (34.4)</td><td align="left" valign="bottom">3017 (39.2)</td></tr><tr><td align="left" valign="bottom"> DR4/DR13</td><td align="left" valign="bottom">54 (0.8)</td><td align="left" valign="bottom">3 (0.5)</td><td align="left" valign="bottom">57 (0.7)</td></tr><tr><td align="left" valign="bottom"> DR4/DR4</td><td align="left" valign="bottom">1444 (20.4)</td><td align="left" valign="bottom">85 (13.8)</td><td align="left" valign="bottom">1529 (19.8)</td></tr><tr><td align="left" valign="bottom"> DR4/DR8</td><td align="left" valign="bottom">1320 (18.6)</td><td align="left" valign="bottom">13 (2.1)</td><td align="left" valign="bottom">1333 (17.3)</td></tr><tr><td align="left" valign="bottom"><bold>Country</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> US</td><td align="left" valign="bottom">2955 (41.7)</td><td align="left" valign="bottom">227 (36.8)</td><td align="left" valign="bottom">3182 (41.3)</td></tr><tr><td align="left" valign="bottom"> SWE</td><td align="left" valign="bottom">2049 (28.9)</td><td align="left" valign="bottom">260 (42.1)</td><td align="left" valign="bottom">2309 (30.0)</td></tr><tr><td align="left" valign="bottom"> FIN</td><td align="left" valign="bottom">1594 (22.5)</td><td align="left" valign="bottom">102 (16.5)</td><td align="left" valign="bottom">1696 (22.0)</td></tr><tr><td align="left" valign="bottom"> GER</td><td align="left" valign="bottom">488 (6.9)</td><td align="left" valign="bottom">28 (4.5)</td><td align="left" valign="bottom">516 (6.7)</td></tr><tr><td align="left" valign="bottom"><bold>FDR</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> No</td><td align="left" valign="bottom">6447 (96.4)</td><td align="left" valign="bottom">496 (80.7)</td><td align="left" valign="bottom">6943 (95.1)</td></tr><tr><td align="left" valign="bottom"> Yes</td><td align="left" valign="bottom">242 (3.6)</td><td align="left" valign="bottom">119 (19.3)</td><td align="left" valign="bottom">361 (4.9)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>All</bold></td><td align="left" valign="bottom">7086 (92.0)</td><td align="left" valign="bottom">617 (8.0)</td><td align="left" valign="bottom">7703 (100)</td></tr></tbody></table></table-wrap><table-wrap id="table7" position="float"><label>Table 7.</label><caption><title>Descriptive characteristics of children with respect to celiac disease autoimmunity (CDA) outcome in number (percentage).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">CDA</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>No</bold></td><td align="left" valign="bottom"><bold>Yes</bold></td><td align="left" valign="bottom"><bold>All</bold></td></tr><tr><td align="left" valign="bottom"><bold>Sex</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Female</td><td align="left" valign="bottom">2555 (47.2)</td><td align="left" valign="bottom">735 (56.8)</td><td align="left" valign="bottom">3290 (49.0)</td></tr><tr><td align="left" valign="bottom"> Male</td><td align="left" valign="bottom">2860 (52.8)</td><td align="left" valign="bottom">559 (43.2)</td><td align="left" valign="bottom">3419 (51.0)</td></tr><tr><td align="left" valign="bottom"><bold>POP</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> EUR</td><td align="left" valign="bottom">4855 (89.7)</td><td align="left" valign="bottom">1237 (95.6)</td><td align="left" valign="bottom">6092 (90.8)</td></tr><tr><td align="left" valign="bottom"> AMR</td><td align="left" valign="bottom">515 (9.5)</td><td align="left" valign="bottom">55 (4.3)</td><td align="left" valign="bottom">570 (8.5)</td></tr><tr><td align="left" valign="bottom"> AFR</td><td align="left" valign="bottom">45 (0.8)</td><td align="left" valign="bottom">2 (0.2)</td><td align="left" valign="bottom">47 (0.7)</td></tr><tr><td align="left" valign="bottom"><bold>HLA Type</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> DR1/DR4</td><td align="left" valign="bottom">134 (2.5)</td><td align="left" valign="bottom">8 (0.6)</td><td align="left" valign="bottom">142 (2.1)</td></tr><tr><td align="left" valign="bottom"> DR3/DR3</td><td align="left" valign="bottom">870 (16.1)</td><td align="left" valign="bottom">530 (41.0)</td><td align="left" valign="bottom">1400 (20.9)</td></tr><tr><td align="left" valign="bottom"> DR3/DR4</td><td align="left" valign="bottom">2146 (39.6)</td><td align="left" valign="bottom">503 (38.9)</td><td align="left" valign="bottom">2649 (39.5)</td></tr><tr><td align="left" valign="bottom"> DR4/DR13</td><td align="left" valign="bottom">46 (0.8)</td><td align="left" valign="bottom">4 (0.3)</td><td align="left" valign="bottom">50 (0.7)</td></tr><tr><td align="left" valign="bottom"> DR4/DR4</td><td align="left" valign="bottom">1130 (20.9)</td><td align="left" valign="bottom">193 (14.9)</td><td align="left" valign="bottom">1323 (19.7)</td></tr><tr><td align="left" valign="bottom"> DR4/DR8</td><td align="left" valign="bottom">1089 (20.1)</td><td align="left" valign="bottom">56 (4.3)</td><td align="left" valign="bottom">1145 (17.1)</td></tr><tr><td align="left" valign="bottom"><bold>Country</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> US</td><td align="left" valign="bottom">2232 (41.2)</td><td align="left" valign="bottom">471 (36.4)</td><td align="left" valign="bottom">2703 (40.3)</td></tr><tr><td align="left" valign="bottom"> SWE</td><td align="left" valign="bottom">1588 (29.3)</td><td align="left" valign="bottom">479 (37.0)</td><td align="left" valign="bottom">2067 (30.8)</td></tr><tr><td align="left" valign="bottom"> FIN</td><td align="left" valign="bottom">1262 (23.3)</td><td align="left" valign="bottom">272 (21.0)</td><td align="left" valign="bottom">1534 (22.9)</td></tr><tr><td align="left" valign="bottom"> GER</td><td align="left" valign="bottom">333 (6.1)</td><td align="left" valign="bottom">72 (5.6)</td><td align="left" valign="bottom">405 (6.0)</td></tr><tr><td align="left" valign="bottom"><bold>FDR</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> No</td><td align="left" valign="bottom">5118 (96.5)</td><td align="left" valign="bottom">1119 (86.9)</td><td align="left" valign="bottom">6237 (94.6)</td></tr><tr><td align="left" valign="bottom"> Yes</td><td align="left" valign="bottom">186 (3.5)</td><td align="left" valign="bottom">169 (13.1)</td><td align="left" valign="bottom">355 (5.4)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>All</bold></td><td align="left" valign="bottom">5415 (80.7)</td><td align="left" valign="bottom">1294 (19.3)</td><td align="left" valign="bottom">6709 (100)</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Tri-SNP association with T1D diagnosis</title><p>5.2% (397/7703) of the children were diagnosed with T1D. 65 were excluded from the time-to-T1D analysis due to missing data for controlled GWAS associations, leaving the final data set for this analysis at 7638, of which 5.2% (395) were diagnosed with T1D. Our model indicated that tri-SNP 101 reduced the risk of developing T1D (HR = 0.54, CI = 0.41–0.72, <italic>p</italic>=1.52e-5, <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Known risk factors HLA DR3/DR4 genotype (HR = 3.20, CI = 2.18–4.70, <italic>p</italic>=3.16e-9) and having an affected FDR (HR = 3.11, CI = 2.42–3.98, <italic>p</italic>=3.75e-19) were the largest risk factors, as expected (<xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref>). All six previously identified GWAS associations with T1D were also significantly associated with T1D diagnosis (<xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref>). While genetic ancestry and sex were not detected as significant risk factors, subjects from Finland were marginally at higher risk (HR = 1.34, <italic>p</italic>=0.04, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="table" rid="table8">Table 8</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cox Proportional Hazard (PH) regression results for all tested outcomes.</title><p>Log hazard ratios (log(HR)) and 95% confidence intervals of the tri-single-nucleotide polymorphism (SNP) 101 haplotype as well as the known risk factors first-degree relative (FDR) and sex from the Cox PH models for outcomes type 1 diabetes (T1D) (<bold>A</bold>), islet antigen (IA) (<bold>B</bold>), insulin autoantibody (IAA)-first (<bold>C</bold>), glutamic acid decarboxylase autoantibody (GADA)-first (<bold>D</bold>), celiac disease (CD) (<bold>E</bold>), and celiac disease autoimmunity (CDA) (<bold>F</bold>), using the entire cohort (left) or only the DR3-DQ2 homozygote individuals (right). Dashed vertical line at 0 indicating an HR of 1 (log(HR)=0), i.e., no effect on risk. Left side of the vertical line indicates reduced risk vs increased risk on the right side. Whiskers indicate 95% CI around HR. The model assesses the independent risk/protection afforded by each covariate compared to the baseline for categorical covariates FDR and sex for which the baselines are having no FDR and female sex, respectively. Tri-SNP 101 is modeled numerically, so the HR reported is per each additional 101 allele.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Complete model output for type 1 diabetes (T1D) outcome.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 7638, N<sub>events</sub> = 395.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Complete model output for type 1 diabetes (T1D) outcome using only DR3-DQ2 homozygotes.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 1589, N<sub>events</sub> = 36.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Complete model output for islet antigen (IA) outcome using all samples.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 7614, N<sub>events</sub> = 855.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Complete model output for islet antigen (IA) outcome using only DR3-DQ2 homozygotes.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 1585, N<sub>events</sub> = 121.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Complete model output for glutamic acid decarboxylase autoantibody (GADA)-first outcome.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 7614, N<sub>events</sub> = 382.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp5-v1.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title>Complete model output for glutamic acid decarboxylase autoantibody (GADA)-first outcome using only DR3-DQ2 homozygotes.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 1585, N<sub>events</sub> = 85.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp6-v1.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 7.</label><caption><title>Complete model output for insulin autoantibody (IAA)-first outcome.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 7614, N<sub>events</sub> = 313.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp7-v1.tif"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 8.</label><caption><title>Complete model output for insulin autoantibody (IAA)-first outcome using only DR3-DQ2 homozygotes.</title><p>HR values and 95% CI are plotted for each covariate included in the model. Vertical line marks the HR = 1 (no change in risk). N<sub>observations</sub> = 1570, N<sub>events</sub> = 29.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp8-v1.tif"/></fig><fig id="fig1s9" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 9.</label><caption><title>Complete model output for celiac disease (CD) outcome.</title><p>log(HR) values and 95% CI are plotted for each covariate included in the model. Vertical line marks the log(HR)=0 (no change in risk). N<sub>observations</sub> = 6530, N<sub>events</sub> = 608.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp9-v1.tif"/></fig><fig id="fig1s10" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 10.</label><caption><title>Complete model output for celiac disease (CD) outcome using only DR3-DQ2 homozygotes.</title><p>log(HR) values and 95% CI are plotted for each covariate included in the model. Vertical line marks the log(HR)=0 (no change in risk). N<sub>observations</sub> = 1364, N<sub>events</sub> = 298.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp10-v1.tif"/></fig><fig id="fig1s11" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 11.</label><caption><title>Complete model output for celiac disease autoimmunity (CDA) outcome.</title><p>log(HR) values and 95% CI are plotted for each covariate included in the model. Vertical line marks the log(HR)=0 (no change in risk). N<sub>observations</sub> = 6557, N<sub>events</sub> = 1282.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp11-v1.tif"/></fig><fig id="fig1s12" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 12.</label><caption><title>Complete model output for celiac disease autoimmunity (CDA) outcome using only DR3-DQ2 homozygotes.</title><p>log(HR) values and 95% CI are plotted for each covariate included in the model. Vertical line marks the log(HR)=0 (no change in risk). N<sub>observations</sub> = 1370, N<sub>events</sub> = 526.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig1-figsupp12-v1.tif"/></fig></fig-group><table-wrap id="table8" position="float"><label>Table 8.</label><caption><title>Previously published Genome-wide association studies (GWAS) associations.</title><p>Single-nucleotide polymorphisms (SNPs) used as covariates in our CoxPH analysis. Celiac disease (CD), celiac disease autoimmunity (CDA), type 1 diabetes (T1D), and islet antigen (IA) columns indicating whether the SNP has been shown to be associated with that outcome and hence used in the model (yes) or not (no). Statistically significant hazard ratios for the associated outcome are also provided under HR columns, protective associations in bold.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">SNP</th><th align="left" valign="bottom">Locus</th><th align="left" valign="bottom">CD</th><th align="left" valign="bottom">CDA</th><th align="left" valign="bottom">T1D</th><th align="left" valign="bottom">IA</th><th align="left" valign="bottom">Publication</th><th align="left" valign="bottom">HR CD</th><th align="left" valign="bottom">HR CDA</th><th align="left" valign="bottom">HR T1D</th><th align="left" valign="bottom">HR IA</th></tr></thead><tbody><tr><td align="left" valign="bottom">rs4851575</td><td align="left" valign="bottom">IL18R1, IL18RAP</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">1.45</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs114569351</td><td align="left" valign="bottom">PLEK,<break/>FBXO48</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">2.64</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs12493471</td><td align="left" valign="bottom">CCR9,<break/>LZTFL1,<break/>CXCR6</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">1.40</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs1054091</td><td align="left" valign="bottom">RSPH3,<break/>TAGAP</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">1.59</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs72704176</td><td align="left" valign="bottom">ASH1L</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">2.26</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs3771689</td><td align="left" valign="bottom">BAZ2B</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"><bold>0.56</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs13014907</td><td align="left" valign="bottom">ZNF804A</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">2.46</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs11739460</td><td align="left" valign="bottom">TCOF1</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">1.41</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs77532435</td><td align="left" valign="bottom">GRB10</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">2.05</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs6967298</td><td align="left" valign="bottom">AUTS2</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"><bold>0.61</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs61751041</td><td align="left" valign="bottom">LAMB1</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">2.23</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs2409747</td><td align="left" valign="bottom">XKR6</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom">1.58</td><td align="left" valign="bottom">1.37</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs12990970</td><td align="left" valign="bottom">NPM1P33,<break/>CTLA4</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>0.76</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs11709472</td><td align="left" valign="bottom">LPP</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>0.80</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs72717025</td><td align="left" valign="bottom">FCGR2A</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">1.84</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs114157400</td><td align="left" valign="bottom">BANK1</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">1.62</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs117561283</td><td align="left" valign="bottom">IFNG</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">1.81</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs8013918</td><td align="left" valign="bottom">FOS</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>0.80</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs73043122</td><td align="left" valign="bottom">RNASET2,<break/>MIR3939</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">3.35</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs113306148</td><td align="left" valign="bottom">PLEKHA1,<break/>MIR3941</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">3.06</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">rs428595</td><td align="left" valign="bottom">PPIL2</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">3.42</td><td align="left" valign="bottom">2.46</td></tr><tr><td align="left" valign="bottom">rs1004446</td><td align="left" valign="bottom">INS</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>0.55</bold></td><td align="left" valign="bottom"><bold>0.67</bold></td></tr><tr><td align="left" valign="bottom">rs2476601</td><td align="left" valign="bottom">PTPN22</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1.91</td><td align="left" valign="bottom">1.73</td></tr><tr><td align="left" valign="bottom">rs2292239</td><td align="left" valign="bottom">ERBB3</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1.68</td><td align="left" valign="bottom">1.45</td></tr><tr><td align="left" valign="bottom">rs3184504</td><td align="left" valign="bottom">SH2B3</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1.40</td></tr><tr><td align="left" valign="bottom">rs9934817</td><td align="left" valign="bottom">RBFOX1</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">2.66</td></tr><tr><td align="left" valign="bottom">rs11705721</td><td align="left" valign="bottom">PXK, PDHB</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">no</td><td align="left" valign="bottom">yes</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1.41</td></tr></tbody></table></table-wrap><p>Given the strong linkage between tri-SNP 101 and HLA DR3 haplotypes (<xref ref-type="table" rid="table1">Table 1</xref>), we performed a separate Cox PH regression using only DR3 homozygous samples for this and each subsequent study outcome. When the analysis was restricted to DR3-DQ2 homozygous children, the protective effect of the 101 tri-SNP was even stronger (HR = 0.35, CI = 0.22–0.56, <italic>p</italic>=1.06e-5, <xref ref-type="fig" rid="fig1">Figure 1A</xref>), confirming our initial report (<xref ref-type="bibr" rid="bib2">Aydemir et al., 2019</xref>) and the confirmatory Finnish report (<xref ref-type="bibr" rid="bib35">Nygård et al., 2021</xref>). Among DR3 homozygous individuals, FDR (HR = 2.86, CI = 1.22–6.67, <italic>p</italic>=0.02) and rs2476601 (PTPN22, HR = 2.51, CI = 1.38–4.56, <italic>p</italic>=0.003) remained significant risk factors (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1B</xref>).</p></sec><sec id="s2-3"><title>Islet autoantibody (IA) development</title><p>At least one IA (the primary TEDDY outcome variable) was detected in 858/7703 (11.1%) children from the dataset. 89 children had missing data for controlled GWAS genotypes and were not included in the Cox PH model for IA outcome. Our model showed a significantly reduced independent risk associated with the tri-SNP 101 haplotype (HR = 0.71, CI = 0.58–0.87, <italic>p</italic>=0.001), each protective allele conferring 29% reduction in risk of developing islet autoantibodies (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Among the controlled covariates, having a first-degree relative (FDR) with T1D (HR = 2.16, CI = 1.78–2.62, <italic>p</italic>=5.76e-15, <xref ref-type="fig" rid="fig1">Figure 1B</xref>), HLA DR3/DR4 genotype (HR = 1.83, CI = 1.41–2.39, <italic>p</italic>=6.96e-6, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1C</xref>) were significant risk factors for IA; and male subjects were found to be at marginally higher risk of developing IA (HR = 1.19, CI = 1.03–1.36, <italic>p</italic>=0.01), consistent with previous TEDDY reports (<xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref>).</p><p>Subjects from Finland (HR = 1.34, CI = 1.11–1.63, <italic>p</italic>=0.002) and Sweden (HR = 1.25, CI = 1.06–1.48, <italic>p</italic>=0.008) were at slightly higher risk than subjects from the United States (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Seven GWAS loci reported to be associated with IA in the TEDDY cohort (<xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref>) were confirmed to be significantly associated and in the same direction (protective vs risk) with IA development in our analysis.</p><p>When analysis was restricted to DR3 homozygous individuals, the protective effect of the tri-SNP 101 haplotype against development of IA was stronger (HR = 0.58, CI = 0.42–0.80, <italic>p</italic>=0.001), each allele conferring 42% reduction in risk. Having an FDR with T1D remained a significant additional risk factor within this group (HR = 2.42, CI = 1.49–3.93, <italic>p</italic>=3.37e-4, <xref ref-type="fig" rid="fig1">Figure 1B</xref>), but other controlled covariates were no longer significant (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1D</xref>).</p></sec><sec id="s2-4"><title>First appearing islet autoantibody</title><p>We assessed the effect of tri-SNP 101 on two T1D autoimmunity endotypes, based on the first appearing islet autoantibody being IAA or glutamic acid decarboxylase autoantibody (GADA) in separate models, controlling for the same covariates as in the IA analysis. Although tri-SNP-101 trended towards protection against GADA-first outcome, this effect did not reach statistical significance either in the entire dataset (HR = 0.87, CI = 0.64–1.17, <italic>p</italic>=0.34, <xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>) or in DR3-DQ2 homozygotes (HR = 0.71, CI = 0.47–1.07, <italic>p</italic>=0.10, <xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1F</xref>). IAA-first risk was significantly reduced by tri-SNP 101 both in the entire data set (HR = 0.64, CI = 0.45–0.91, <italic>p</italic>=0.01, <xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1G</xref>) and the DR3-DQ2 homozygotes (HR = 0.48, CI = 0.25–0.91, <italic>p</italic>=0.03, <xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s8">Figure 1—figure supplement 8</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1H</xref>). We note that since the incidence of IAA-first among DR3-DQ2 homozygotes at 1.8% (29/1578) is relatively low, samples from an African genetic background (N=32, incidence = 0), and one low-frequency GWAS locus were excluded from this analysis to accommodate the model requirements.</p></sec><sec id="s2-5"><title>Celiac Diagnosis (CD)</title><p>Among the study subjects, 617 (8.0%) were diagnosed with CD. 24 children had both T1D and CD which corresponded to 3.9% of all CD samples and 6.0% of all T1D samples. 6530 children had complete information on all covariates for CD and these were used in the Cox PH time-to-CD analysis.</p><p>In contrast to its protective effect against T1D, tri-SNP 101 was a significant risk factor (HR = 1.32, CI = 1.06–1.64, <italic>p</italic>=0.01, <xref ref-type="fig" rid="fig1">Figure 1E</xref>) for CD. As previously reported, female sex, FDR, gluten intake, and HLA-DR3, and HLA-DR4 haplotypes were significant risk factors (<xref ref-type="bibr" rid="bib1">Andrén Aronsson et al., 2019</xref>), (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1s9">Figure 1—figure supplement 9</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1I</xref>). Previously identified GWAS associations (<xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref>) were also observed in our analysis. Individuals assigned to AMR genetic ancestry were at lower risk of CD (HR = 0.62, <italic>p</italic>=0.04) compared to the baseline EUR population (<xref ref-type="fig" rid="fig1s9">Figure 1—figure supplement 9</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1I</xref>).</p><p>The increased CD risk associated with the 101 tri-SNP haplotype remained significant (HR = 1.32, CI = 1.02–1.70, <italic>p</italic>=0.04) when the analysis was restricted to HLA-DR3 homozygotes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1s10">Figure 1—figure supplement 10</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1J</xref>).</p></sec><sec id="s2-6"><title>Celiac Disease Autoimmunity (CDA) Development</title><p>6709 children had CDA data available. 19.2% (1294) were positive for CDA. 174 showed both CDA and IA corresponding to 13.4% of all CDA and 21.3% of all IA individuals. 6557 children had complete information for all covariates used in the statistical model.</p><p>Similar to its effect on CD and contrary to T1D and IA, the tri-SNP 101 haplotype was a significant risk factor (HR = 1.23, CI = 1.06–1.44, <italic>p</italic>=0.008) for CDA (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Other risk factors included FDR with celiac disease, female sex, HLA-DR3 and DR4 haplotypes, gluten intake, and European genetic ancestry, all of which have been reported previously (<xref ref-type="bibr" rid="bib1">Andrén Aronsson et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Singh et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s11">Figure 1—figure supplement 11</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1K</xref>).</p><p>Tri-SNP 101 remained a risk factor when the analysis was restricted to DR3-DQ2 homozygotes (HR = 1.23, CI = 1.02–1.48, <italic>p</italic>=0.03, <xref ref-type="fig" rid="fig1s12">Figure 1—figure supplement 12</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1L</xref>).</p></sec><sec id="s2-7"><title>Comparison to HLA-DR3 B8 extended haplotype</title><p>It has been reported that two conserved extended haplotypes carrying DR3 (B8-DR3 and B18-DR3) differentially contribute to the risk for T1D and CD in the Basque population (<xref ref-type="bibr" rid="bib7">Bilbao et al., 2006</xref>). Our analysis shows that the tri-SNP 101 haplotype is weakly correlated with the CD-predisposing B8-DR3 extended haplotype (R<sup>2</sup>=0.32 for DR3 homozygotes, data not shown). However, when the Cox proportional hazard model was fitted using the B8 dosage instead of the tri-SNP, the associations with T1D (B8 HR = 0.64 vs tri-SNP HR = 0.54, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1M</xref>) and IA (B8 HR = 0.80 vs tri-SNP HR = 0.71, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1N</xref>) were weaker, and no significant association was detected either for CD (HR = 1.11, <italic>p</italic>=0.12, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1O</xref>) or for CDA (HR = 1.07, <italic>p</italic>=0.20, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1P</xref>).</p></sec><sec id="s2-8"><title>Differential Gene Expression</title><p>We explored the leukocyte gene expression differences within 538 samples from 129 DR3-DQ2 homozygous individuals of our study cohort. Expression of 68 genes were found to be significantly affected by the tri-SNP 101 haplotype (adjusted-p &lt;0.01, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1Q</xref>). Eight of 10 of the most significant changes were affected genes located in the MHC loci.</p><p>The expression of complement system genes C4A and C4B was inversely affected by the tri-SNP 101 dosage (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Whereas C4A gene expression decreased (<italic>p</italic>=1.46E-22), C4B significantly increased (<italic>p</italic>=5.32E-13) with increasing tri-SNP 101 dosage.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>C4 gene expression values with respect to tri-single-nucleotide polymorphism (SNP).</title><p>Count per million (CPM) values in 129 DR3 homozygous individuals showing decreasing C4A and increasing C4B gene expression as tri-SNP 101 allele count increases. Each point represents the median CPM value of multiple samples from one individual. Boxes represent the interquartile range (IQR) and midlines mark the median value.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig2-v1.tif"/></fig></sec><sec id="s2-9"><title>Copy Number Variation in C4 Locus</title><p>The C4 locus has been reported to have frequent copy number variation and associations with autoimmunity (<xref ref-type="bibr" rid="bib30">Li et al., 2017</xref>). We analyzed the whole genome sequencing data of 188 DR3-DQ2 homozygous individuals from our cohort to investigate whether there are copy number changes in C4A or C4B. Read coverage data showed reduced coverage of C4 genes in some samples indicating the presence of gene deletions (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Due to extensive sequence identity between C4A and C4B, determination of C4A and C4B copy numbers was based only on reads mapping uniquely to either gene (<xref ref-type="fig" rid="fig3">Figure 3</xref>). We identified frequent C4A deletions: 56.9% (107/188) of the samples were C4A null, and 23.4% had only a single C4A (<xref ref-type="table" rid="table9">Table 9</xref>). All 107 C4A null samples were homozygous for tri-SNP 101 genotype indicating a strong association (chi-squared <italic>p</italic>-value = 5.59E-38). C4B deletions were also common, although not as frequent as C4A. There was only one C4B null sample and 22.8% (43/188) of the samples had a single C4B gene (<xref ref-type="table" rid="table10">Table 10</xref>). We observed a positive association between tri-SNP 101 and C4B copy number (chi-squared <italic>p</italic>-value = 1.89E-20) in contrast to the negative correlation with C4A. We also noted that 89.4% (168/188) of samples had total C4 gene copy number &lt;4.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Unique sequence read coverage in C4 region and copy number calls.</title><p>Uniquely mapping read coverage from whole genome sequencing (WGS) data of 188 homozygous DR3-DQ2 individuals. C4A and C4B genes share extensive sequence identity along the genes except a ~3 kilobase region indicated with boxes. Reads mapping to these regions were used to estimate C4A (left column) and C4B (right column) copy numbers per sample. Samples were sorted based on C4A copy numbers. A maximum value of 4 was used for the heatmap to moderate high outlier values.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Sequence read coverage in C4 region.</title><p>(<bold>A</bold>) Normalized read coverage from whole genome sequencing (WGS) data of 188 homozygous DR3-DQ2 individuals. Reduced coverage of C4 genes relative to the flanking regions indicates the presence of frequent gene deletions. Total C4 copy numbers per sample indicated on the left side of the heatmap were estimated based on the average coverage per sample in C4 region demarcated with blue boxes below the heatmap, including both C4A and C4B but excluding reads mapping to intronic HERV insertion. A maximum value of 4 was used for the heatmap to moderate high outlier values. (<bold>B</bold>) Histograms and the kernel density estimates (kde) of the sample distribution based on average read coverage for C4 (blue boxes below heatmap) and copy number invariant flanking regions (gray boxes below heatmap). Flanking regions show a tight distribution with a peak around 2 indicating normal/diploid status. C4 coverage distribution shows three peaks around 1, 1.5, and 2; most likely corresponding to 2, 3, and 4 total copies. (<bold>C</bold>) Distribution of unique coverage corresponding to C4A and C4B genes (see <xref ref-type="fig" rid="fig3">Figure 3</xref>). Major C4A peak at 0 coverage indicating C4A null samples and peaks around 0.3 and 0.6 are likely 1 and 2 copies of C4A, respectively. C4B distribution shows a single null sample as well as 2 peaks around 0.3 and 0.6.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89068-fig3-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table9" position="float"><label>Table 9.</label><caption><title>Estimated C4A gene copy number with respect to tri-single-nucleotide polymorphism (SNP) haplotype.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">tri-SNP 101</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>C4A copy number</bold></td><td align="left" valign="bottom"><bold>0</bold></td><td align="left" valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><bold>2</bold></td></tr><tr><td align="left" valign="bottom"><bold>0</bold></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">107</td></tr><tr><td align="left" valign="bottom"><bold>1</bold></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">44</td><td align="left" valign="bottom">10</td></tr><tr><td align="left" valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">9</td><td align="left" valign="bottom">7</td></tr><tr><td align="left" valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">1</td></tr></tbody></table></table-wrap><table-wrap id="table10" position="float"><label>Table 10.</label><caption><title>Estimated C4B gene copy number with respect to tri-single-nucleotide polymorphism (SNP) haplotype.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">tri-SNP 101</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>C4B copy number</bold></td><td align="left" valign="bottom"><bold>0</bold></td><td align="left" valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><bold>2</bold></td></tr><tr><td align="left" valign="bottom"><bold>0</bold></td><td align="left" valign="bottom">1</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><bold>1</bold></td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">34</td><td align="left" valign="bottom">4</td></tr><tr><td align="left" valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">17</td><td align="left" valign="bottom">119</td></tr><tr><td align="left" valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">2</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We report confirmation of the tri-SNP association with T1D in a much larger, independent cohort. In addition, we show that the 101 tri-SNP haplotype is also associated with reduced risk of developing IA. Although the primary outcome of the TEDDY study was IA, it has been recognized in multiple studies that there may be two distinct ‘endotypes’ of T1D autoimmunity based on the timing of emergence of specific autoantibodies (<xref ref-type="bibr" rid="bib6">Battaglia et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Johnson et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Krischer et al., 2015</xref>). One of the proposed endotypes is characterized by the appearance of IAA early on as the first marker of IA, termed ‘IAA-first’, and it is associated with HLA DR4-DQ8 haplotype. The second endotype is marked by the emergence at a later time of GAD autoantibodies as the first IA marker, termed ‘GADA-first,’ is associated with DR3-DQ2 haplotype (<xref ref-type="bibr" rid="bib26">Krischer et al., 2015</xref>). We show that the tri-SNP is significantly associated with protection from the IAA-first outcome but not the GADA-first outcome, indicating that the main T1D protective effect of tri-SNP may be due to delay or prevention of insulin autoantibody generation. This may explain the low incidence of the IAA-first endotype among DR3-DQ2 carrying individuals, given the enrichment of the protective tri-SNP allele on the DR3-DQ2 chromosomes.</p><p>Unexpectedly, we discovered that the T1D-protective tri-SNP 101 haplotype is associated with <italic>increased</italic> risk for both autoantibody development (CDA) and clinical CD. This finding is surprising because CD and T1D are thought to share genetic risk factors not only because of the increased co-occurrence of the two pathologies but also because DR3-DQ2 and DR4-DQ8 are major genetic loci for susceptibility for both disorders. An extended HLA-DR3 haplotype (B8) was described in the literature as having a differential impact on T1D and CD development in a small sample set of the Basque population (<xref ref-type="bibr" rid="bib7">Bilbao et al., 2006</xref>) but this was not replicated in our sample set. Therefore, the opposite effects of the tri-SNP haplotype on the risk of T1D and CD in our cohort are novel and independent of the extended B8 haplotype.</p><p>Tri-SNP is a valuable addition to the collection of known genetic and environmental factors that are used to predict T1D and CD (<xref ref-type="bibr" rid="bib9">Bonifacio et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Romanos et al., 2014</xref>). Knowing whether a high-risk HLA child is more likely to develop T1D or CD may aid in decisions about early therapeutic or preventive interventions, such as a strict gluten-free diet or preventive anti-CD3 antibody treatment (<xref ref-type="bibr" rid="bib23">Herold et al., 2019</xref>). Our findings advance our understanding of complex polygenic diseases and should provide a more precise risk/benefit assessment of potential treatments based on data.</p><p>Furthermore, we investigated potential mechanisms underlying the differential association of tri-SNP with T1D and CD by analyzing gene expression differences based on the tri-SNP genotype. Complement system genes C4A and C4B emerged as intriguing candidates whose expression changed in opposite direction with respect to tri-SNP genotype. C4 locus has been reported to have frequent copy number variation (<xref ref-type="bibr" rid="bib30">Li et al., 2017</xref>). Therefore, we explored whether the gene expression changes we observe may be due to changes in gene copy numbers (GCN). Indeed, tri-SNP 101, which is associated with decreased C4A and increased C4B gene expression, was also associated with frequent C4A gene deletions and increased C4B GCN. We also observed that close to 90% of our samples were missing at least one C4 gene. Reduced C4 GCN have been associated with the development of autoimmune diseases, such as systemic lupus erythematosus (<xref ref-type="bibr" rid="bib38">Pereira et al., 2016</xref>), juvenile dermatomyositis (<xref ref-type="bibr" rid="bib31">Lintner et al., 2016</xref>), and rheumatoid arthritis (<xref ref-type="bibr" rid="bib42">Rigby et al., 2012</xref>). In addition, lower serum levels of C4 protein have been suggested to predispose to T1D (<xref ref-type="bibr" rid="bib55">Vergani et al., 1983</xref>). Taken together, reduced total C4 GCN frequent in our high-risk HLA cohort is in line with the reports of increased susceptibility of low C4 to autoimmune diseases, and the different disease outcomes based on the tri-SNP haplotype may be, in part, due to the absence of specific C4 genes carried on that haplotype. Although the link between tri-SNP and C4 GCN is intriguing, independent association analyses for C4 genes and diseases were not possible due to the small number of samples with the GCN data. In addition, given the presence of other differentially expressed genes in the MHC locus, it is possible that the differential risk marked by tri-SNP is due to multiple factors.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Study population</title><p>Data were obtained from participants in the TEDDY prospective cohort study, whose primary goal is to identify environmental causes of T1D. It includes three clinical research centers in the United States (Colorado, Georgia/Florida, Washington) and three in Europe (Finland, Germany, and Sweden), and has been described in detail (<xref ref-type="bibr" rid="bib52">The TEDDY Study Group, 2007</xref>; <xref ref-type="bibr" rid="bib51">TEDDY Study Group, 2008</xref>). Briefly, participation in the study was offered to the parents of all newborns at each research center. Inclusion criteria were based on HLA genotype and are described below. Separate written informed consents were obtained for all study participants from a parent or primary caretaker for genetic screening and for participation in prospective follow-up. The study was approved by local Institutional Review Boards and is monitored by an external advisory board formed by the National Institutes of Health.</p><sec id="s4-1-1"><title>Inclusion criteria</title><p>Genotype screening (<xref ref-type="bibr" rid="bib21">Hagopian et al., 2011</xref>) was conducted using either a dried blood spot punch or a small volume whole blood lysate specimen as described (<xref ref-type="bibr" rid="bib13">Dantonio et al., 2010</xref>). Infants were eligible for the study if they had 2 high-risk HLA genotypes or had a first-degree relative with T1D and at least one high-risk HLA genotype. Details of these inclusion criteria are as follows:</p><p>Infants from the general population were eligible for the study if they had any one of the following HLA genotypes (excluding those with DR4 subtype DRB1*04:03):</p><list list-type="order" id="list1"><list-item><p>DR3-DQA1*05:01-DQB1*02:01/DR4-DQA1*03:0X-DQB1*03:02</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR4-DQA1*03:0X-DQB1*03:02</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR8-DQA1*04:01-DQB1*04:02</p></list-item><list-item><p>DR3-DQA1*05:01-DQB1*02:01/DR3-DQA1*05:01-DQB1*02:01</p></list-item></list><p>Infants with a first-degree relative with T1D were eligible for enrollment if they had any of the following HLA genotypes:</p><list list-type="order" id="list2"><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR3-DQA1*05:01-DQB1*02:01</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR4-DQA1*03:0X-DQB1*03:02</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR8-DQA1*04:01-DQB1*04:02</p></list-item><list-item><p>DR3-DQA1*05:01-DQB1*02:01/DR3-DQA1*05:01-DQB1*02:01</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR4-DQA1*03:0X-DQB1*02:0 X</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR12-DQA1*01:01-DQB1*05:01</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR13-DQA1*01:02-DQB1*06:04</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR4-DQA1*03:0X-DQB1*03:04</p></list-item><list-item><p>DR4-DQA1*03:0X-DQB1*03:02/DR9-DQA1*03:0X-DQB1*03:03</p></list-item><list-item><p>DR3-DQA1*05:01-DQB1*02:01/DR9-DQA1*03:0X-DQB1*03:03</p></list-item></list></sec><sec id="s4-1-2"><title>HLA nomenclature</title><p>Explanation of HLA nomenclature used is as follows: DR3=DRB1*03:01; DR4=DRB1*04:01, *04:02, *04:04, *04:05, or *04:07; DQA1*03:0X=any DQA1*03; DQB1*03:02=DQB1*03:02 or DQB1*03:04; DQB1*02:0X=any DQB1*02; DR8=any DRB1*08; DR9=DRB1*09:01; DR12=any DRB1*12; DR13=any DRB1*13.</p></sec><sec id="s4-1-3"><title>HLA typing</title><p>Screening blood samples were generally obtained at birth from cord blood. Other potential participants, especially first-degree relatives of T1D participants at the Washington site, were screened using heel stick capillary samples up to the age of 4 months. This exception was made to maximize the number of newborn relatives participating in this study. After polymerase chain reaction (PCR) amplification of exon 2 of the HLA Class II gene (DRB1, DQA1, or DQB1), alleles are identified either by direct sequencing, oligonucleotide probe hybridization, or other genotyping techniques as described (<xref ref-type="bibr" rid="bib21">Hagopian et al., 2011</xref>). Additional typing to sufficiently identify certain DR-DQ haplotypes was specific to each clinical center.</p><p>When a TEDDY participant was 9–12 months of age, HLA status was confirmed by genotyping at increased resolution of HLA-DRB1, DQA1, and DQB1 at the central HLA reference laboratory at Roche Molecular Systems, Oakland, CA (<xref ref-type="bibr" rid="bib17">Erlich et al., 1991</xref>). SNPs from the Illumina Immuno BeadChip (manifest file: Immuno_BeadChip_11419691.bpm from Illumina, San Diego, CA, USA) were also assessed by the Center for Public Health Genomics at the University of Virginia as described previously (<xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref>).</p></sec></sec><sec id="s4-2"><title>Study design</title><sec id="s4-2-1"><title>Primary outcome definition</title><p>The primary TEDDY outcome variable was the development of persistent, confirmed IA. IA was assessed every 3 months through four years of age. Persistent autoimmunity was defined by the confirmed (two reference labs in agreement) presence of any one of three islet autoantibodies:IAA, GADA, or insulinoma antigen-2 (IA-2A) on two or more consecutive visits. Date of persistent autoimmunity was defined as the draw date of the first sample of the two consecutive autoantibody-positive samples.</p></sec><sec id="s4-2-2"><title>Islet autoantibodies</title><p>Islet autoantibodies were the first primary endpoint in the TEDDY study. Islet autoantibodies to insulin, GAD65, and IA-2 were measured in two laboratories by radiobinding assays (<xref ref-type="bibr" rid="bib4">Babaya et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Bonifacio et al., 2010</xref>). In the U.S., all sera were assayed at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver; in Europe, all sera were assayed at the University of Bristol, the U.K. Assays in both laboratories have previously demonstrated high sensitivity, specificity, and concordance (<xref ref-type="bibr" rid="bib53">Törn et al., 2008</xref>). All positive islet autoantibodies and 5% of negative samples were re-tested in the other reference laboratory and deemed confirmed if concordant. To optimize concordance, harmonized assays for GADA and IA-2A replaced earlier assays in January 2010 (Based on a receiver-operator curve analysis, prior samples that needed to be re-analyzed with the harmonized assays included: Denver GADA between –0.015 and 0.042; Bristol GADA between 10.69 and 36.72; Denver IA-2A between –0.004 and 0.016; and Bristol IA-2A between 6.69 and 10.58). To distinguish maternal antibodies from IA in the child, the IA status of the mother was measured when the child was aged 9 months, and the child’s IA status was measured at 3 months of age and then every three months until 18 months of age. If the child had positive IA during this time, the status was listed as ‘pending’ until 18 months of age, at which time the child’s IA status was determined based on both maternal and child IA over the first 18 months of the study. If maternal antibodies were present, the child was not considered persistently IA positive until positive at/after 18 months, unless the child had a negative sample prior to their first positive sample. A recognized limitation of this approach is that true IA positivity during the first 18 months of life that waned could have been masked by maternal antibodies.</p></sec><sec id="s4-2-3"><title>Diagnosis of T1D and CD</title><p>T1D and CD were the second primary endpoints in the TEDDY study. At the time of clinical diagnosis of diabetes, data were collected outside the TEDDY clinics (care providers or clinics) using a standardized case report form requiring documentation to fulfill American Diabetes Association criteria for classification of T1D (<xref ref-type="bibr" rid="bib16">Elding Larsson et al., 2014</xref>).</p><p>TEDDY children were screened for tTGA using radiobinding assays from 2 years of age and annually thereafter. TEDDY samples from the US sites were analyzed at the Barbara Davis Center and samples from the European sites at the Bristol University, which was chosen as the reference laboratory as previously described (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>). All samples from US children with a tTGA level &gt;0.01 units were sent to the Bristol laboratory for analysis. Children with a positive tTGA had additional samples collected at three-month intervals to 48 months of age, and at 6-month intervals after the 48 month visit. In addition, all tTGA positive children had previously collected samples analyzed to find the closest time point to conversion. Children with a positive tTGA result in two consecutive samples were defined as having CDA (i.e. primary outcome) and referred to local health care providers for follow-up and clinical evaluation of CD. The decision to perform a diagnostic intestinal biopsy was outside the TEDDY protocol, but it was recommended by the TEDDY investigators of Celiac Disease Committee to biopsy CDA children with tTGA levels 30 units or greater in CDA children with gastrointestinal symptoms regardless of tTGA level. Diagnosis of CD per se was defined as an intestinal biopsy showing a Marsh score &gt;1, or if a biopsy was not performed, having a mean tTGA level of 100 units or greater in two consecutive samples (i.e. secondary outcome), respectively.</p></sec></sec><sec id="s4-3"><title>Statistical and computational analyses</title><sec id="s4-3-1"><title>Whole genome sequencing</title><p>Whole genome sequencing (WGS) was conducted on the subjects based on the IA and T1D nested case–control (NCC) studies with targeted 30× coverage by Macrogen, Inc, Rockville, MD, U.S.A as described previously (<xref ref-type="bibr" rid="bib54">Törn et al., 2022</xref>). Joint variant discovery and genotype calling was performed by combining TEDDY and TOPMed WGS data using the topmed_variant_calling pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/statgen/topmed_variant_calling">https://github.com/statgen/topmed_variant_calling</ext-link>; <xref ref-type="bibr" rid="bib28">LeFaive and Min Kang, 2024</xref>; <xref ref-type="bibr" rid="bib50">Taliun et al., 2021</xref>).</p></sec><sec id="s4-3-2"><title>Determination of tri-SNP haplotype</title><p>Tri-SNP haplotypes were extracted from the ImmunoChip or WGS phased variant call file using scikit-allel software v1.3.5 (<ext-link ext-link-type="uri" xlink:href="https://scikit-allel.readthedocs.io/en/stable/">https://scikit-allel.readthedocs.io/en/stable/</ext-link>).</p></sec><sec id="s4-3-3"><title>Determination of B8-DR3 haplotype</title><p>Extended haplotype status of the individuals was imputed based on a subset of 203 SNPs whose non-reference alleles were associated with the B8-DR3 haplotype (<italic>A*01:01-B*08:01-DRB1*03:01</italic>) (<xref ref-type="bibr" rid="bib18">Gourraud et al., 2014</xref>). The ImmunoChip variant calls contained 79 of these variants, whereas the WGS data contained 200. The individuals were assigned a B8-DR3 dosage based on the mode of the alternative allele counts of all SNPs, i.e., 0 if most SNPs were called homozygous reference genotype, 1 if most loci were heterozygous, and 2 if most loci were homozygous alternate allele.</p></sec><sec id="s4-3-4"><title>Genetic ancestry inference</title><p>Out of 7759 individuals, 5277 (68.0%) had self-reported race/ethnicity information as African American (65), Hispanic (558), and White non-Hispanic (4654). These were assigned to AFR, AMR, and EUR superpopulation groups, respectively. The remaining 2482 individuals' population membership was inferred using the software Kinship-based INference for Gwas (KING v2.2.7, <xref ref-type="bibr" rid="bib33">Manichaikul et al., 2010</xref>) ancestry inference commands (<monospace>king -b reference.bed,samples.bed --pca --projection</monospace>). Briefly, the program uses 2409 samples from the 1000 Genomes Project with known population information to create Principal Components (PCs) and projects the study samples onto these PCs based on their genetic variation data (from ImmunoChip and Whole Genome Sequencing for TEDDY samples). Python sklearn library’s (v0.24.2) RandomForestClassifier module was used to assign population membership using the PCs generated by KING. The classifier’s performance was assessed by splitting the 2409 individuals from 1000 Genomes Project with known ancestry into training (70%) and test (30%) sets which showed an accuracy of 99.6%. For ancestry assignment of study samples, all 2409 samples from the 1000 Genomes Project were used as the training data and all 7903 TEDDY samples (all samples with genetic data, including those that were not in the final data set, e.g., with ineligible HLA types) as test data. Study samples where the ancestry information was reported were compared to the classifier predictions which showed 95.6% concordance. The inferred population information was used only for the 2482 samples that did not have the self-reported ancestry data.</p></sec><sec id="s4-3-5"><title>Statistical model</title><p>The Cox Proportional Hazards (PH) method was used to analyze the impact of tri-SNP haplotypes on primary and secondary T1D and CD disease outcomes. T1D diagnosis, islet autoimmunity (IA), first-appearing islet autoantibody, celiac diagnosis (CD), and celiac disease autoantibody (CDA) status were defined as events in separate models; age of the subject (in months) was used as the time component. When the event was not observed, age at the latest clinic visit (for CD or T1D) or at the last negative serum sample collection (for IA and CDA) was used as the right-censor time. In the first appearing autoantibody models, samples were right-censored if any other antibody than the one in the model outcome first appeared.</p><p>Known risk factors, including HLA type, sex, having a first-degree relative with the disease and genetic variants previously shown to be associated with each outcome (<xref ref-type="table" rid="table8">Table 8</xref>; <xref ref-type="bibr" rid="bib27">Krischer et al., 2017</xref>; <xref ref-type="bibr" rid="bib46">Sharma et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Sharma et al., 2018</xref>), as well as potential confounders, including ancestry/ethnicity and the country of residence were included in the model to adjust for them. Tri-SNP 101 allele was modeled as a numerical variable (0, 1, or 2 alleles) representing an additive genetic effect, and hence, its hazard ratio values should be interpreted as HR per each additional allele. Similarly, the known GWAS loci were encoded numerically (0, 1, 2 alternate alleles). For the categorical covariates HLA type, sex, country, and genetic ancestry, the baselines were assigned to DR4/DR8, female, USA, and EUR, respectively. Cox PH modeling was carried out using the Lifelines Python library v0.26.3 (<xref ref-type="bibr" rid="bib14">Davidson-Pilon, 2019</xref>).</p></sec><sec id="s4-3-6"><title>RNA sequence analysis</title><p>The RNA samples were prepared using Illumina’s TruSeq Stranded mRNA Sample Prep Kit from the whole blood samples. RNA sequencing was conducted using the Illumina HiSeq4000 platform with paired-end 2×101 bp reads with a targeted 50 million reads per sample by the Broad Institute, Cambridge, MA. Gene expression was quantified using Salmon software v1.6.0 (<xref ref-type="bibr" rid="bib37">Patro et al., 2017</xref>) and the Gencode v39 transcript set. Differential gene expression analysis was carried out using limma v3.48.3 (<xref ref-type="bibr" rid="bib43">Ritchie et al., 2015</xref>) with the design formula ‘~batch + age + sex + triSNP 101’ to account for differences due to sequencing batch, age, and the sex of each sample. Age was modeled as a categorical: younger or older than 1 year old as the major difference due to age was in children younger than 1 based on PCA analysis of gene expression data (not shown). Multiple samples from the same individual were accounted for by using the individual as the blocking factor as recommended in the limma user manual. Independent effect of triSNP-101 was extracted from the model using the <italic>topTable</italic> function and coefficient triSNP 101.</p></sec><sec id="s4-3-7"><title>Copy number analysis</title><p>A bed file containing 1 kilobase non-overlapping windows for MHC region (chromosome 6 positions 28510000–33482000) was created. MHC locus read coverage for each sample was extracted from WGS reads mapped to human genome assembly hg38 using samtools v1.16.1 bedcov command and the MHC bed file. ‘-Q 30’ option was used for counting uniquely mapping reads. The average normalized coverage for C4A and C4B genes using uniquely mapping reads (<xref ref-type="fig" rid="fig3">Figure 3</xref>), as well as combined C4 average coverage using all reads (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>) were calculated.</p></sec><sec id="s4-3-8"><title>Total C4 GCN estimation</title><p>We estimated the total C4 GCN based on the read coverage of the C4 region, including C4A and C4B but excluding the intronic HERV insertion (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Histograms of per sample coverage for C4 region, as well as 25 kilobases flanking regions on both sides, were plotted (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). While the flanking regions showed a single peak around 2, indicating a normal diploid status; C4 region showed three peaks around 1, 1.5, and 2, likely representing 2, 3, and 4 GCNs, respectively. Since the three peaks in the C4 histogram was well separated, we estimated total C4 GCN based on these peaks: samples under the first peak (coverage &lt;1.4) were assigned 2 GCN; those under the second peak (1.4 &lt; coverage &lt; 1.9) were assigned 3 GCN and those under the third peak (coverage &gt;1.9) were assigned 4 GCN.</p></sec><sec id="s4-3-9"><title>C4A and C4B GCN estimation</title><p>Histograms of coverage based on reads uniquely mapping to either C4A or C4B were created (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). We observed a major peak at 0 coverage for C4A, indicating total C4A deletions and a separate peak around 0.3 indicating 1 GCN; and 2 peaks for C4B around 0.3 and 0.6, which likely indicate GCNs of 1 and 2. Since total gene deletions were well separated in the histograms for C4A and C4B, we first assigned the GCNs of C4A or C4B null samples (average coverage below 0.04). However, because the peaks for 1 and 2 GCNs were not clearly separated, the rest of the C4A and C4B GCNs were estimated based on the total C4 GCN and the ratio of unique coverage of C4A and C4B. The exact heuristic used was: if a sample was C4A null, C4B was assigned the same value as total C4 GCN; if C4B was null, C4A was assigned the C4 GCN. For samples where neither C4A nor C4B was null: if C4 GCN was 2, C4A and C4B each were assigned 1 GCN; if C4 GCN was 3, C4A and C4B coverage were compared and larger received 2 GCN and smaller 1 GCN; if C4 GCN was 4, C4A and C4B were each assigned 2 GCN unless the coverage ratio between them was larger than 2.5, in which case the gene with more coverage was assigned 3 and the other 1 GCN.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Formal analysis, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Data curation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Data curation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Resources</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Supervision, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Clinical trial registration NCT00279318.</p></fn><fn fn-type="other"><p>Data were obtained from participants in the TEDDY prospective cohort study which has been described in detail (Teddy Study Group, 2007, 2008). The TEDDY study was approved by local US Institutional Review Boards and European Ethics Committee Boards, including the Colorado Multiple Institutional Review Board, Medical College of Georgia Human Assurance Committee (2004-2010), Georgia Health Sciences University Human Assurance Committee (2011-2012), Georgia Regents University Institutional Review Board (2013-2015), Augusta University Institutional Review Board (2015-present), University of Florida Health Center Institutional Review Board, Washington State Institutional Review Board (2004-2012), Western Institutional Review Board (2013-present), Ethics Committee of the Hospital District of Southwest Finland, Bayerische Landesärztekammer (Bavarian Medical Association) Ethics Committee, Regional Ethics Board in Lund, Section 2 (2004-2012), and Lund University Committee for Continuing Ethical Review (2013-present). All parents or guardians provided written informed consent before participation in genetic screening and enrollment. There was no compensation provided to participants. The analysis of the anonymized data provided by TEDDY to UMass was judged by UMass Institutional Review Board as an exempt study.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-89068-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Numerical results from all CoxPH analysis and differential gene expression analysis.</title></caption><media xlink:href="elife-89068-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The code and source data for the analyses presented in this paper, including all numerical data used to generate each figure/table and all deidentified clinical data, are available and openly accessible at <ext-link ext-link-type="uri" xlink:href="https://github.com/aydemiro/mp257">https://github.com/aydemiro/mp257</ext-link> (copy archived at <xref ref-type="bibr" rid="bib3">Aydemir, 2025</xref>). ImmunoChip, RNA-sequencing, and whole-genome sequencing data were generated as part of the The Environmental Determinants of Diabetes in the Young (TEDDY) study and submitted to the dbGaP repository (Study Accession: phs001442.v4.p3). Data from TEDDY study (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.58020/y3jk-x087">https://doi.org/10.58020/y3jk-x087</ext-link>) reported here will be made available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), <ext-link ext-link-type="uri" xlink:href="https://repository.niddk.nih.gov/">https://repository.niddk.nih.gov/</ext-link>. The data are available under controlled access in accordance with dbGaP and NIDDK authorization to ensure that data are shared for type 1 diabetes and related disease research consistent with the TEDDY study participants' consent and protect participant privacy. Data access requests can be submitted directly to NIDDK-CR and dbGaP through their respective websites. These requests are reviewed by an assigned NIH Data Access Committee, and both repositories have eligibility requirements that investigators must meet to submit requests.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2008">2008</year><data-title>The Environmental Determinants of Diabetes in the Young Study (TEDDY)</data-title><source>NCBI dbGaP</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001442.v4.p3">phs001442.v4.p3</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Krischer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>The Environmental Determinants of Diabetes in the Young (TEDDY)</data-title><source>NIDDK Central Repository</source><pub-id pub-id-type="doi">10.58020/y3jk-x087</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>Full details for the TEDDY Study Group can be found in Appendix 1. The TEDDY Study is funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4 DK112243, UC4 DK117483, U01 DK124166, U01 DK128847, and Contract No. HHSN267200700014C from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF. This work is supported in part by the NIH/NCATS Clinical and Translational Science Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR002535). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrén Aronsson</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>H-S</given-names></name><name><surname>Hård Af Segerstad</surname><given-names>EM</given-names></name><name><surname>Uusitalo</surname><given-names>U</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Koletzko</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Kurppa</surname><given-names>K</given-names></name><name><surname>Bingley</surname><given-names>PJ</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>She</surname><given-names>J-X</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Virtanen</surname><given-names>SM</given-names></name><name><surname>Norris</surname><given-names>JM</given-names></name><name><surname>Agardh</surname><given-names>D</given-names></name><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Association of gluten intake during the first 5 years of life with incidence of celiac disease autoimmunity and celiac disease among children at increased risk</article-title><source>JAMA</source><volume>322</volume><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.10329</pub-id><pub-id pub-id-type="pmid">31408136</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydemir</surname><given-names>Ö</given-names></name><name><surname>Noble</surname><given-names>JA</given-names></name><name><surname>Bailey</surname><given-names>JA</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Marsh</surname><given-names>P</given-names></name><name><surname>Andersson Svärd</surname><given-names>A</given-names></name><name><surname>Bearoff</surname><given-names>F</given-names></name><name><surname>Blankenhorn</surname><given-names>EP</given-names></name><name><surname>Mordes</surname><given-names>JP</given-names></name><collab>Better Diabetes Diagnosis (BDD) Study Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic variation within the <italic>HLA-DRA1</italic> gene modulates susceptibility to type 1 diabetes in HLA-DR3 homozygotes</article-title><source>Diabetes</source><volume>68</volume><fpage>1523</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.2337/db18-1128</pub-id><pub-id pub-id-type="pmid">30962219</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Aydemir</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Mp257</data-title><version designator="swh:1:rev:ca438858976a6143c041690bb64f92fc900848f6">swh:1:rev:ca438858976a6143c041690bb64f92fc900848f6</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:8dd7f061843c6ef987435ecf578459f88e750e91;origin=https://github.com/aydemiro/mp257;visit=swh:1:snp:d7da3851e4a663e7c33e947164c85205de098287;anchor=swh:1:rev:ca438858976a6143c041690bb64f92fc900848f6">https://archive.softwareheritage.org/swh:1:dir:8dd7f061843c6ef987435ecf578459f88e750e91;origin=https://github.com/aydemiro/mp257;visit=swh:1:snp:d7da3851e4a663e7c33e947164c85205de098287;anchor=swh:1:rev:ca438858976a6143c041690bb64f92fc900848f6</ext-link></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaya</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Barker</surname><given-names>JM</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Comparison of insulin autoantibody: polyethylene glycol and micro-IAA 1-day and 7-day assays</article-title><source>Diabetes/Metabolism Research and Reviews</source><volume>25</volume><fpage>665</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1014</pub-id><pub-id pub-id-type="pmid">19768733</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranzini</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The genetics of autoimmune diseases: a networked perspective</article-title><source>Current Opinion in Immunology</source><volume>21</volume><fpage>596</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.09.014</pub-id><pub-id pub-id-type="pmid">19896815</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battaglia</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>MS</given-names></name><name><surname>Atkinson</surname><given-names>MA</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name><name><surname>Bingley</surname><given-names>PJ</given-names></name><name><surname>Bosi</surname><given-names>E</given-names></name><name><surname>Brusko</surname><given-names>TM</given-names></name><name><surname>DiMeglio</surname><given-names>LA</given-names></name><name><surname>Evans-Molina</surname><given-names>C</given-names></name><name><surname>Gitelman</surname><given-names>SE</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name><name><surname>Gottlieb</surname><given-names>PA</given-names></name><name><surname>Herold</surname><given-names>KC</given-names></name><name><surname>Hessner</surname><given-names>MJ</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><name><surname>Jacobsen</surname><given-names>L</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Long</surname><given-names>SA</given-names></name><name><surname>Lundgren</surname><given-names>M</given-names></name><name><surname>McKinney</surname><given-names>EF</given-names></name><name><surname>Morgan</surname><given-names>NG</given-names></name><name><surname>Oram</surname><given-names>RA</given-names></name><name><surname>Pastinen</surname><given-names>T</given-names></name><name><surname>Peters</surname><given-names>MC</given-names></name><name><surname>Petrelli</surname><given-names>A</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Redondo</surname><given-names>MJ</given-names></name><name><surname>Roep</surname><given-names>BO</given-names></name><name><surname>Schatz</surname><given-names>D</given-names></name><name><surname>Skibinski</surname><given-names>D</given-names></name><name><surname>Peakman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes</article-title><source>Diabetes Care</source><volume>43</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.2337/dc19-0880</pub-id><pub-id pub-id-type="pmid">31753960</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilbao</surname><given-names>JR</given-names></name><name><surname>Calvo</surname><given-names>B</given-names></name><name><surname>Aransay</surname><given-names>AM</given-names></name><name><surname>Martin-Pagola</surname><given-names>A</given-names></name><name><surname>Perez de Nanclares</surname><given-names>G</given-names></name><name><surname>Aly</surname><given-names>TA</given-names></name><name><surname>Rica</surname><given-names>I</given-names></name><name><surname>Vitoria</surname><given-names>JC</given-names></name><name><surname>Gaztambide</surname><given-names>S</given-names></name><name><surname>Noble</surname><given-names>J</given-names></name><name><surname>Fain</surname><given-names>PR</given-names></name><name><surname>Awdeh</surname><given-names>ZL</given-names></name><name><surname>Alper</surname><given-names>CA</given-names></name><name><surname>Castaño</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Conserved extended haplotypes discriminate HLA-DR3-homozygous Basque patients with type 1 diabetes mellitus and celiac disease</article-title><source>Genes and Immunity</source><volume>7</volume><fpage>550</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6364328</pub-id><pub-id pub-id-type="pmid">16929349</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>AK</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Bingley</surname><given-names>PJ</given-names></name><name><surname>Marcovina</surname><given-names>SM</given-names></name><name><surname>Adler</surname><given-names>K</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Mueller</surname><given-names>PW</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>95</volume><fpage>3360</fpage><lpage>3367</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-0293</pub-id><pub-id pub-id-type="pmid">20444913</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Beyerlein</surname><given-names>A</given-names></name><name><surname>Hippich</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>C</given-names></name><name><surname>Vehik</surname><given-names>K</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Laimighofer</surname><given-names>M</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Krumsiek</surname><given-names>J</given-names></name><name><surname>Frohnert</surname><given-names>BI</given-names></name><name><surname>Steck</surname><given-names>AK</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Rewers</surname><given-names>MJ</given-names></name><name><surname>She</surname><given-names>J-X</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Oram</surname><given-names>RA</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Ziegler</surname><given-names>A-G</given-names></name><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children</article-title><source>PLOS Medicine</source><volume>15</volume><elocation-id>e1002548</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1002548</pub-id><pub-id pub-id-type="pmid">29614081</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradfield</surname><given-names>JP</given-names></name><name><surname>Qu</surname><given-names>H-Q</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sleiman</surname><given-names>PM</given-names></name><name><surname>Kim</surname><given-names>CE</given-names></name><name><surname>Mentch</surname><given-names>FD</given-names></name><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Glessner</surname><given-names>JT</given-names></name><name><surname>Thomas</surname><given-names>KA</given-names></name><name><surname>Frackelton</surname><given-names>EC</given-names></name><name><surname>Chiavacci</surname><given-names>RM</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Monos</surname><given-names>DS</given-names></name><name><surname>Pandey</surname><given-names>R</given-names></name><name><surname>Bakay</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>SFA</given-names></name><name><surname>Polychronakos</surname><given-names>C</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci</article-title><source>PLOS Genetics</source><volume>7</volume><elocation-id>e1002293</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002293</pub-id><pub-id pub-id-type="pmid">21980299</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>NK</given-names></name><name><surname>Guandalini</surname><given-names>S</given-names></name><name><surname>Semrad</surname><given-names>C</given-names></name><name><surname>Kupfer</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A clinician’s guide to celiac disease HLA genetics</article-title><source>The American Journal of Gastroenterology</source><volume>114</volume><fpage>1587</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000000310</pub-id><pub-id pub-id-type="pmid">31274511</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlquist</surname><given-names>G</given-names></name><name><surname>Blom</surname><given-names>L</given-names></name><name><surname>Tuvemo</surname><given-names>T</given-names></name><name><surname>Nyström</surname><given-names>L</given-names></name><name><surname>Sandström</surname><given-names>A</given-names></name><name><surname>Wall</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>The Swedish childhood diabetes study--results from a nine year case register and a one year case-referent study indicating that type 1 (insulin-dependent) diabetes mellitus is associated with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders</article-title><source>Diabetologia</source><volume>32</volume><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/BF00265396</pub-id><pub-id pub-id-type="pmid">2707516</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantonio</surname><given-names>P</given-names></name><name><surname>Meredith-Molloy</surname><given-names>N</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Cordovado</surname><given-names>SK</given-names></name><name><surname>Hendrix</surname><given-names>M</given-names></name><name><surname>Henderson</surname><given-names>LO</given-names></name><name><surname>Hannon</surname><given-names>WH</given-names></name><name><surname>Vogt</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots</article-title><source>Journal of Diabetes Science and Technology</source><volume>4</volume><fpage>929</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1177/193229681000400424</pub-id><pub-id pub-id-type="pmid">20663459</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson-Pilon</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>lifelines: survival analysis in Python</article-title><source>Journal of Open Source Software</source><volume>4</volume><elocation-id>1317</elocation-id><pub-id pub-id-type="doi">10.21105/joss.01317</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vitis</surname><given-names>I</given-names></name><name><surname>Ghirlanda</surname><given-names>G</given-names></name><name><surname>Gasbarrini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Prevalence of coeliac disease in type I diabetes: a multicentre study</article-title><source>Acta Paediatrica</source><volume>85</volume><fpage>56</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.1996.tb14253.x</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elding Larsson</surname><given-names>H</given-names></name><name><surname>Vehik</surname><given-names>K</given-names></name><name><surname>Gesualdo</surname><given-names>P</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Krischer</surname><given-names>J</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name><name><surname>She</surname><given-names>J-X</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name><name><surname>Haller</surname><given-names>MJ</given-names></name><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease</article-title><source>Pediatric Diabetes</source><volume>15</volume><fpage>118</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1111/pedi.12066</pub-id><pub-id pub-id-type="pmid">24034790</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erlich</surname><given-names>H</given-names></name><name><surname>Bugawan</surname><given-names>T</given-names></name><name><surname>Begovich</surname><given-names>AB</given-names></name><name><surname>Scharf</surname><given-names>S</given-names></name><name><surname>Griffith</surname><given-names>R</given-names></name><name><surname>Saiki</surname><given-names>R</given-names></name><name><surname>Higuchi</surname><given-names>R</given-names></name><name><surname>Walsh</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>HLA‐DR, DO and DP typing using PCR amplification and immobilized probes</article-title><source>International Journal of Immunogenetics</source><volume>18</volume><fpage>33</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.1744-313X.1991.tb00005.x</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gourraud</surname><given-names>PA</given-names></name><name><surname>Khankhanian</surname><given-names>P</given-names></name><name><surname>Cereb</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Feolo</surname><given-names>M</given-names></name><name><surname>Maiers</surname><given-names>M</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Hauser</surname><given-names>S</given-names></name><name><surname>Oksenberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>HLA diversity in the 1000 genomes dataset</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e97282</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0097282</pub-id><pub-id pub-id-type="pmid">24988075</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez-Achury</surname><given-names>J</given-names></name><name><surname>Zhernakova</surname><given-names>A</given-names></name><name><surname>Pulit</surname><given-names>SL</given-names></name><name><surname>Trynka</surname><given-names>G</given-names></name><name><surname>Hunt</surname><given-names>KA</given-names></name><name><surname>Romanos</surname><given-names>J</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>van Heel</surname><given-names>DA</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>de Bakker</surname><given-names>PIW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fine mapping in the MHC region accounts for 18% additional genetic risk for celiac disease</article-title><source>Nature Genetics</source><volume>47</volume><fpage>577</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/ng.3268</pub-id><pub-id pub-id-type="pmid">25894500</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez-Arcelus</surname><given-names>M</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autoimmune diseases - connecting risk alleles with molecular traits of the immune system</article-title><source>Nature Reviews. Genetics</source><volume>17</volume><fpage>160</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1038/nrg.2015.33</pub-id><pub-id pub-id-type="pmid">26907721</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>Erlich</surname><given-names>H</given-names></name><name><surname>Lernmark</surname><given-names>A</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Vogt</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Blair</surname><given-names>A</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name><name><surname>Krischer</surname><given-names>J</given-names></name><name><surname>She</surname><given-names>J</given-names></name><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2011">2011</year><article-title>The environmental determinants of diabetes in the young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants</article-title><source>Pediatric Diabetes</source><volume>12</volume><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5448.2011.00774.x</pub-id><pub-id pub-id-type="pmid">21564455</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Erlich</surname><given-names>H</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Agardh</surname><given-names>D</given-names></name><name><surname>Group</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Co-occurrence of type 1 diabetes and celiac disease autoimmunity</article-title><source>Pediatrics</source><volume>140</volume><elocation-id>e20171305</elocation-id><pub-id pub-id-type="doi">10.1542/peds.2017-1305</pub-id><pub-id pub-id-type="pmid">29018046</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>KC</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Long</surname><given-names>SA</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>DiMeglio</surname><given-names>LA</given-names></name><name><surname>Dufort</surname><given-names>MJ</given-names></name><name><surname>Gitelman</surname><given-names>SE</given-names></name><name><surname>Gottlieb</surname><given-names>PA</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><name><surname>Marks</surname><given-names>JB</given-names></name><name><surname>Moore</surname><given-names>W</given-names></name><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Rodriguez</surname><given-names>H</given-names></name><name><surname>Russell</surname><given-names>WE</given-names></name><name><surname>Schatz</surname><given-names>D</given-names></name><name><surname>Skyler</surname><given-names>JS</given-names></name><name><surname>Tsalikian</surname><given-names>E</given-names></name><name><surname>Wherrett</surname><given-names>DK</given-names></name><name><surname>Ziegler</surname><given-names>A-G</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name><collab>Type 1 Diabetes TrialNet Study Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes</article-title><source>The New England Journal of Medicine</source><volume>381</volume><fpage>603</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1902226</pub-id><pub-id pub-id-type="pmid">31180194</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husby</surname><given-names>S</given-names></name><name><surname>Koletzko</surname><given-names>S</given-names></name><name><surname>Korponay-Szabó</surname><given-names>IR</given-names></name><name><surname>Mearin</surname><given-names>ML</given-names></name><name><surname>Phillips</surname><given-names>A</given-names></name><name><surname>Shamir</surname><given-names>R</given-names></name><name><surname>Troncone</surname><given-names>R</given-names></name><name><surname>Giersiepen</surname><given-names>K</given-names></name><name><surname>Branski</surname><given-names>D</given-names></name><name><surname>Catassi</surname><given-names>C</given-names></name><name><surname>Lelgeman</surname><given-names>M</given-names></name><name><surname>Mäki</surname><given-names>M</given-names></name><name><surname>Ribes-Koninckx</surname><given-names>C</given-names></name><name><surname>Ventura</surname><given-names>A</given-names></name><name><surname>Zimmer</surname><given-names>KP</given-names></name><collab>ESPGHAN Working Group on Coeliac Disease Diagnosis</collab><collab>ESPGHAN Gastroenterology Committee</collab><collab>European Society for Pediatric Gastroenterology, Hepatology, and Nutrition</collab></person-group><year iso-8601-date="2012">2012</year><article-title>European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease</article-title><source>Journal of Pediatric Gastroenterology and Nutrition</source><volume>54</volume><fpage>136</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e31821a23d0</pub-id><pub-id pub-id-type="pmid">22197856</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SB</given-names></name><name><surname>Lynch</surname><given-names>KF</given-names></name><name><surname>Roth</surname><given-names>R</given-names></name><name><surname>Lundgren</surname><given-names>M</given-names></name><name><surname>Parikh</surname><given-names>HM</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Krischer</surname><given-names>J</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Group</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>First-appearing islet autoantibodies for type 1 diabetes in young children: maternal life events during pregnancy and the child’s genetic risk</article-title><source>Diabetologia</source><volume>64</volume><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1007/s00125-020-05344-9</pub-id><pub-id pub-id-type="pmid">33404683</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Lynch</surname><given-names>KF</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>Rewers</surname><given-names>MJ</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Simell</surname><given-names>OG</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Group</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study</article-title><source>Diabetologia</source><volume>58</volume><fpage>980</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1007/s00125-015-3514-y</pub-id><pub-id pub-id-type="pmid">25660258</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Lynch</surname><given-names>KF</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>Rewers</surname><given-names>MJ</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Group</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study</article-title><source>Diabetes Care</source><volume>40</volume><fpage>1194</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.2337/dc17-0238</pub-id><pub-id pub-id-type="pmid">28646072</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>LeFaive</surname><given-names>J</given-names></name><name><surname>Min Kang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Topmed_variant_calling</data-title><version designator="e4d45fb">e4d45fb</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/statgen/topmed_variant_calling">https://github.com/statgen/topmed_variant_calling</ext-link></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>MM</given-names></name><name><surname>Sapone</surname><given-names>A</given-names></name><name><surname>Catassi</surname><given-names>C</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Celiac disease and nonceliac gluten sensitivity: a review</article-title><source>JAMA</source><volume>318</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.9730</pub-id><pub-id pub-id-type="pmid">28810029</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Association between C4, C4A, and C4B copy number variations and susceptibility to autoimmune diseases: a meta-analysis</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>42628</elocation-id><pub-id pub-id-type="doi">10.1038/srep42628</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lintner</surname><given-names>KE</given-names></name><name><surname>Patwardhan</surname><given-names>A</given-names></name><name><surname>Rider</surname><given-names>LG</given-names></name><name><surname>Abdul-Aziz</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Lundström</surname><given-names>E</given-names></name><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Alhomosh</surname><given-names>A</given-names></name><name><surname>Newsom</surname><given-names>D</given-names></name><name><surname>White</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>KB</given-names></name><name><surname>O’Hanlon</surname><given-names>TP</given-names></name><name><surname>Miller</surname><given-names>FW</given-names></name><name><surname>Spencer</surname><given-names>CH</given-names></name><name><surname>Yu</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis</article-title><source>Annals of the Rheumatic Diseases</source><volume>75</volume><fpage>1599</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2015-207762</pub-id><pub-id pub-id-type="pmid">26493816</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>H-S</given-names></name><name><surname>Aronsson</surname><given-names>CA</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>Koletzko</surname><given-names>S</given-names></name><name><surname>Rewers</surname><given-names>MJ</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Bingley</surname><given-names>PJ</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Simell</surname><given-names>V</given-names></name><name><surname>Agardh</surname><given-names>D</given-names></name><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Risk of pediatric celiac disease according to HLA haplotype and country</article-title><source>The New England Journal of Medicine</source><volume>371</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1313977</pub-id><pub-id pub-id-type="pmid">24988556</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manichaikul</surname><given-names>A</given-names></name><name><surname>Mychaleckyj</surname><given-names>JC</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Daly</surname><given-names>K</given-names></name><name><surname>Sale</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Robust relationship inference in genome-wide association studies</article-title><source>Bioinformatics</source><volume>26</volume><fpage>2867</fpage><lpage>2873</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq559</pub-id><pub-id pub-id-type="pmid">20926424</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>JA</given-names></name><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Varney</surname><given-names>MD</given-names></name><name><surname>Carlson</surname><given-names>JA</given-names></name><name><surname>Moonsamy</surname><given-names>P</given-names></name><name><surname>Fear</surname><given-names>AL</given-names></name><name><surname>Lane</surname><given-names>JA</given-names></name><name><surname>Lavant</surname><given-names>E</given-names></name><name><surname>Rappner</surname><given-names>R</given-names></name><name><surname>Louey</surname><given-names>A</given-names></name><name><surname>Concannon</surname><given-names>P</given-names></name><name><surname>Mychaleckyj</surname><given-names>JC</given-names></name><name><surname>Erlich</surname><given-names>HA</given-names></name><collab>Type 1 Diabetes Genetics Consortium</collab></person-group><year iso-8601-date="2010">2010</year><article-title>HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium</article-title><source>Diabetes</source><volume>59</volume><fpage>2972</fpage><lpage>2979</lpage><pub-id pub-id-type="doi">10.2337/db10-0699</pub-id><pub-id pub-id-type="pmid">20798335</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nygård</surname><given-names>L</given-names></name><name><surname>Laine</surname><given-names>A-P</given-names></name><name><surname>Kiviniemi</surname><given-names>M</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Härkönen</surname><given-names>T</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><name><surname>Veijola</surname><given-names>R</given-names></name><name><surname>Lempainen</surname><given-names>J</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tri-SNP polymorphism in the intron of HLA-DRA1 affects type 1 diabetes susceptibility in the Finnish population</article-title><source>Human Immunology</source><volume>82</volume><fpage>912</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2021.07.010</pub-id><pub-id pub-id-type="pmid">34311991</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkkola</surname><given-names>A</given-names></name><name><surname>Härkönen</surname><given-names>T</given-names></name><name><surname>Ryhänen</surname><given-names>SJ</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><collab>Finnish Pediatric Diabetes Register</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children</article-title><source>Diabetes Care</source><volume>36</volume><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.2337/dc12-0445</pub-id><pub-id pub-id-type="pmid">23033245</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patro</surname><given-names>R</given-names></name><name><surname>Duggal</surname><given-names>G</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Kingsford</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title><source>Nature Methods</source><volume>14</volume><fpage>417</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id><pub-id pub-id-type="pmid">28263959</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>KMC</given-names></name><name><surname>Faria</surname><given-names>AGA</given-names></name><name><surname>Liphaus</surname><given-names>BL</given-names></name><name><surname>Jesus</surname><given-names>AA</given-names></name><name><surname>Silva</surname><given-names>CA</given-names></name><name><surname>Carneiro-Sampaio</surname><given-names>M</given-names></name><name><surname>Andrade</surname><given-names>LEC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Low C4, C4A and C4B gene copy numbers are stronger risk factors for juvenile-onset than for adult-onset systemic lupus erythematosus</article-title><source>Rheumatology</source><volume>55</volume><fpage>869</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kev436</pub-id><pub-id pub-id-type="pmid">26800705</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>BG</given-names></name><name><surname>Eberwine</surname><given-names>R</given-names></name><name><surname>Noble</surname><given-names>JA</given-names></name><name><surname>Habib</surname><given-names>M</given-names></name><name><surname>Shulha</surname><given-names>HP</given-names></name><name><surname>Weng</surname><given-names>Z</given-names></name><name><surname>Blankenhorn</surname><given-names>EP</given-names></name><name><surname>Mordes</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The missing heritability in T1D and potential new targets for prevention</article-title><source>Journal of Diabetes Research</source><volume>2013</volume><elocation-id>737485</elocation-id><pub-id pub-id-type="doi">10.1155/2013/737485</pub-id><pub-id pub-id-type="pmid">23691517</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polychronakos</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Understanding type 1 diabetes through genetics: advances and prospects</article-title><source>Nature Reviews. Genetics</source><volume>12</volume><fpage>781</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1038/nrg3069</pub-id><pub-id pub-id-type="pmid">22005987</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Bugawan</surname><given-names>TL</given-names></name><name><surname>Norris</surname><given-names>JM</given-names></name><name><surname>Blair</surname><given-names>A</given-names></name><name><surname>Beaty</surname><given-names>B</given-names></name><name><surname>Hoffman</surname><given-names>M</given-names></name><name><surname>McDuffie</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Hamman</surname><given-names>RF</given-names></name><name><surname>Klingensmith</surname><given-names>G</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Erlich</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY)</article-title><source>Diabetologia</source><volume>39</volume><fpage>807</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1007/s001250050514</pub-id><pub-id pub-id-type="pmid">8817105</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigby</surname><given-names>WFC</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Zan</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Rosengren</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>C</given-names></name><name><surname>Hilton</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Increased frequency of complement C4B deficiency in rheumatoid arthritis</article-title><source>Arthritis and Rheumatism</source><volume>64</volume><fpage>1338</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1002/art.33472</pub-id><pub-id pub-id-type="pmid">22076784</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>CC</given-names></name><name><surname>Inshaw</surname><given-names>JRJ</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>Santa Cruz</surname><given-names>DF</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Cutler</surname><given-names>AJ</given-names></name><name><surname>Crouch</surname><given-names>DJM</given-names></name><name><surname>Farber</surname><given-names>E</given-names></name><name><surname>Bridges</surname><given-names>SL</given-names><suffix>Jr</suffix></name><name><surname>Edberg</surname><given-names>JC</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name><name><surname>Buckner</surname><given-names>JH</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Divers</surname><given-names>J</given-names></name><name><surname>Dabelea</surname><given-names>D</given-names></name><name><surname>Lawrence</surname><given-names>JM</given-names></name><name><surname>Marcovina</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>AS</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name><name><surname>Atkinson</surname><given-names>MA</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Oksenberg</surname><given-names>JR</given-names></name><name><surname>Pociot</surname><given-names>F</given-names></name><name><surname>Rewers</surname><given-names>MJ</given-names></name><name><surname>Steck</surname><given-names>AK</given-names></name><name><surname>Dunger</surname><given-names>DB</given-names></name><name><surname>Wicker</surname><given-names>LS</given-names></name><name><surname>Concannon</surname><given-names>P</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><collab>Type 1 Diabetes Genetics Consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes</article-title><source>Nature Genetics</source><volume>53</volume><fpage>962</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00880-5</pub-id><pub-id pub-id-type="pmid">34127860</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romanos</surname><given-names>J</given-names></name><name><surname>Rosén</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Trynka</surname><given-names>G</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name><name><surname>Szperl</surname><given-names>A</given-names></name><name><surname>Gutierrez-Achury</surname><given-names>J</given-names></name><name><surname>van Diemen</surname><given-names>CC</given-names></name><name><surname>Kanninga</surname><given-names>R</given-names></name><name><surname>Jankipersadsing</surname><given-names>SA</given-names></name><name><surname>Steck</surname><given-names>A</given-names></name><name><surname>Eisenbarth</surname><given-names>G</given-names></name><name><surname>van Heel</surname><given-names>DA</given-names></name><name><surname>Cukrowska</surname><given-names>B</given-names></name><name><surname>Bruno</surname><given-names>V</given-names></name><name><surname>Mazzilli</surname><given-names>MC</given-names></name><name><surname>Núñez</surname><given-names>C</given-names></name><name><surname>Bilbao</surname><given-names>JR</given-names></name><name><surname>Mearin</surname><given-names>ML</given-names></name><name><surname>Barisani</surname><given-names>D</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>JM</given-names></name><name><surname>Ivarsson</surname><given-names>A</given-names></name><name><surname>Boezen</surname><given-names>HM</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><collab>PreventCD Group</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants</article-title><source>Gut</source><volume>63</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-304110</pub-id><pub-id pub-id-type="pmid">23704318</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hadley</surname><given-names>D</given-names></name><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Simell</surname><given-names>V</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Agardh</surname><given-names>D</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Group</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of Non-HLA genes associated with celiac disease and country-specific differences in a large, international pediatric cohort</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0152476</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0152476</pub-id><pub-id pub-id-type="pmid">27015091</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hadley</surname><given-names>D</given-names></name><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Törn</surname><given-names>C</given-names></name><name><surname>Steck</surname><given-names>AK</given-names></name><name><surname>Frohnert</surname><given-names>BI</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Group</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of non-HLA genes associated with development of islet autoimmunity and type 1 diabetes in the prospective TEDDY cohort</article-title><source>Journal of Autoimmunity</source><volume>89</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2017.12.008</pub-id><pub-id pub-id-type="pmid">29310926</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Lal</surname><given-names>S</given-names></name><name><surname>Strand</surname><given-names>TA</given-names></name><name><surname>Makharia</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Risk of celiac disease in the first- and second-degree relatives of patients with celiac disease: a systematic review and meta-analysis</article-title><source>The American Journal of Gastroenterology</source><volume>110</volume><fpage>1539</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1038/ajg.2015.296</pub-id><pub-id pub-id-type="pmid">26416192</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szaflarska-Popławska</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Coexistence of coeliac disease and type 1 diabetes</article-title><source>Przeglad Gastroenterologiczny</source><volume>9</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.5114/pg.2014.40844</pub-id><pub-id pub-id-type="pmid">24868293</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taliun</surname><given-names>D</given-names></name><name><surname>Harris</surname><given-names>DN</given-names></name><name><surname>Kessler</surname><given-names>MD</given-names></name><name><surname>Carlson</surname><given-names>J</given-names></name><name><surname>Szpiech</surname><given-names>ZA</given-names></name><name><surname>Torres</surname><given-names>R</given-names></name><name><surname>Taliun</surname><given-names>SAG</given-names></name><name><surname>Corvelo</surname><given-names>A</given-names></name><name><surname>Gogarten</surname><given-names>SM</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Pitsillides</surname><given-names>AN</given-names></name><name><surname>LeFaive</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S-B</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Browning</surname><given-names>BL</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Emde</surname><given-names>A-K</given-names></name><name><surname>Clarke</surname><given-names>WE</given-names></name><name><surname>Loesch</surname><given-names>DP</given-names></name><name><surname>Shetty</surname><given-names>AC</given-names></name><name><surname>Blackwell</surname><given-names>TW</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Wong</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Conomos</surname><given-names>MP</given-names></name><name><surname>Bobo</surname><given-names>DM</given-names></name><name><surname>Aguet</surname><given-names>F</given-names></name><name><surname>Albert</surname><given-names>C</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Arking</surname><given-names>DE</given-names></name><name><surname>Aslibekyan</surname><given-names>S</given-names></name><name><surname>Auer</surname><given-names>PL</given-names></name><name><surname>Barnard</surname><given-names>J</given-names></name><name><surname>Barr</surname><given-names>RG</given-names></name><name><surname>Barwick</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>LC</given-names></name><name><surname>Beer</surname><given-names>RL</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Bielak</surname><given-names>LF</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Bowden</surname><given-names>DW</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Burchard</surname><given-names>EG</given-names></name><name><surname>Cade</surname><given-names>BE</given-names></name><name><surname>Casella</surname><given-names>JF</given-names></name><name><surname>Chalazan</surname><given-names>B</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><name><surname>Chen</surname><given-names>Y-DI</given-names></name><name><surname>Cho</surname><given-names>MH</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><name><surname>Correa</surname><given-names>A</given-names></name><name><surname>Curran</surname><given-names>JE</given-names></name><name><surname>Custer</surname><given-names>B</given-names></name><name><surname>Darbar</surname><given-names>D</given-names></name><name><surname>Daya</surname><given-names>M</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Dutcher</surname><given-names>SK</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Emery</surname><given-names>LS</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Fatkin</surname><given-names>D</given-names></name><name><surname>Fingerlin</surname><given-names>T</given-names></name><name><surname>Forer</surname><given-names>L</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Franceschini</surname><given-names>N</given-names></name><name><surname>Fuchsberger</surname><given-names>C</given-names></name><name><surname>Fullerton</surname><given-names>SM</given-names></name><name><surname>Germer</surname><given-names>S</given-names></name><name><surname>Gladwin</surname><given-names>MT</given-names></name><name><surname>Gottlieb</surname><given-names>DJ</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Hall</surname><given-names>ME</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Heard-Costa</surname><given-names>NL</given-names></name><name><surname>Heckbert</surname><given-names>SR</given-names></name><name><surname>Irvin</surname><given-names>MR</given-names></name><name><surname>Johnsen</surname><given-names>JM</given-names></name><name><surname>Johnson</surname><given-names>AD</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Kardia</surname><given-names>SLR</given-names></name><name><surname>Kelly</surname><given-names>T</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Kenny</surname><given-names>EE</given-names></name><name><surname>Kiel</surname><given-names>DP</given-names></name><name><surname>Klemmer</surname><given-names>R</given-names></name><name><surname>Konkle</surname><given-names>BA</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Köttgen</surname><given-names>A</given-names></name><name><surname>Lange</surname><given-names>LA</given-names></name><name><surname>Lasky-Su</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>K-H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Garman</surname><given-names>L</given-names></name><name><surname>Gerszten</surname><given-names>R</given-names></name><name><surname>Lubitz</surname><given-names>SA</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Mak</surname><given-names>ACY</given-names></name><name><surname>Manichaikul</surname><given-names>A</given-names></name><name><surname>Manning</surname><given-names>AK</given-names></name><name><surname>Mathias</surname><given-names>RA</given-names></name><name><surname>McManus</surname><given-names>DD</given-names></name><name><surname>McGarvey</surname><given-names>ST</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name><name><surname>Mikulla</surname><given-names>JL</given-names></name><name><surname>Minear</surname><given-names>MA</given-names></name><name><surname>Mitchell</surname><given-names>BD</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Montasser</surname><given-names>ME</given-names></name><name><surname>Montgomery</surname><given-names>C</given-names></name><name><surname>Morrison</surname><given-names>AC</given-names></name><name><surname>Murabito</surname><given-names>JM</given-names></name><name><surname>Natale</surname><given-names>A</given-names></name><name><surname>Natarajan</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>SC</given-names></name><name><surname>North</surname><given-names>KE</given-names></name><name><surname>O’Connell</surname><given-names>JR</given-names></name><name><surname>Palmer</surname><given-names>ND</given-names></name><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Peyser</surname><given-names>PA</given-names></name><name><surname>Pleiness</surname><given-names>J</given-names></name><name><surname>Post</surname><given-names>WS</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Rao</surname><given-names>DC</given-names></name><name><surname>Redline</surname><given-names>S</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Roden</surname><given-names>D</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Ruczinski</surname><given-names>I</given-names></name><name><surname>Sarnowski</surname><given-names>C</given-names></name><name><surname>Schoenherr</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Seo</surname><given-names>J-S</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>Sheehan</surname><given-names>VA</given-names></name><name><surname>Sheu</surname><given-names>WH</given-names></name><name><surname>Shoemaker</surname><given-names>MB</given-names></name><name><surname>Smith</surname><given-names>NL</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Sotoodehnia</surname><given-names>N</given-names></name><name><surname>Stilp</surname><given-names>AM</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Telen</surname><given-names>M</given-names></name><name><surname>Thornton</surname><given-names>TA</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Van Den Berg</surname><given-names>DJ</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Viaud-Martinez</surname><given-names>KA</given-names></name><name><surname>Vrieze</surname><given-names>S</given-names></name><name><surname>Weeks</surname><given-names>DE</given-names></name><name><surname>Weir</surname><given-names>BS</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Weng</surname><given-names>L-C</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Ashley-Koch</surname><given-names>AE</given-names></name><name><surname>Barnes</surname><given-names>KC</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Gibbs</surname><given-names>R</given-names></name><name><surname>Rice</surname><given-names>KM</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><name><surname>Qasba</surname><given-names>P</given-names></name><name><surname>Gan</surname><given-names>W</given-names></name><collab>NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium</collab><name><surname>Papanicolaou</surname><given-names>GJ</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Browning</surname><given-names>SR</given-names></name><name><surname>Zody</surname><given-names>MC</given-names></name><name><surname>Zöllner</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Laurie</surname><given-names>CC</given-names></name><name><surname>Jaquish</surname><given-names>CE</given-names></name><name><surname>Hernandez</surname><given-names>RD</given-names></name><name><surname>O’Connor</surname><given-names>TD</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program</article-title><source>Nature</source><volume>590</volume><fpage>290</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03205-y</pub-id><pub-id pub-id-type="pmid">33568819</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2008">2008</year><article-title>The environmental determinants of diabetes in the young (TEDDY) study</article-title><source>Annals of the New York Academy of Sciences</source><volume>1150</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1196/annals.1447.062</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The TEDDY Study Group</collab></person-group><year iso-8601-date="2007">2007</year><article-title>The environmental determinants of diabetes in the young (TEDDY) study: study design</article-title><source>Pediatric Diabetes</source><volume>8</volume><fpage>286</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5448.2007.00269.x</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Törn</surname><given-names>C</given-names></name><name><surname>Mueller</surname><given-names>PW</given-names></name><name><surname>Schlosser</surname><given-names>M</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Bingley</surname><given-names>PJ</given-names></name><collab>Participating Laboratories</collab></person-group><year iso-8601-date="2008">2008</year><article-title>Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2</article-title><source>Diabetologia</source><volume>51</volume><fpage>846</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1007/s00125-008-0967-2</pub-id><pub-id pub-id-type="pmid">18373080</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Törn</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Counts</surname><given-names>KM</given-names></name><name><surname>Moreno</surname><given-names>JL</given-names></name><name><surname>Remedios</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>LeFaive</surname><given-names>J</given-names></name><name><surname>Butterworth</surname><given-names>MD</given-names></name><name><surname>Akolkar</surname><given-names>B</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Lernmark</surname><given-names>Å</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Toppari</surname><given-names>J</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Ratan</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Parikh</surname><given-names>HM</given-names></name><collab>TEDDY Study Group</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Telomere length is not a main factor for the development of islet autoimmunity and type 1 diabetes in the TEDDY study</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>4516</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-08058-7</pub-id><pub-id pub-id-type="pmid">35296692</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergani</surname><given-names>D</given-names></name><name><surname>Johnston</surname><given-names>C</given-names></name><name><surname>B-Abdullah</surname><given-names>N</given-names></name><name><surname>Barnett</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Low serum C4 concentrations: an inherited predisposition to insulin dependent diabetes?</article-title><source>British Medical Journal</source><volume>286</volume><fpage>926</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1136/bmj.286.6369.926</pub-id><pub-id pub-id-type="pmid">6403137</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Beyond genetics: what causes type 1 diabetes</article-title><source>Clinical Reviews in Allergy &amp; Immunology</source><volume>52</volume><fpage>273</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s12016-016-8592-1</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>The TEDDY Study Group membership</title><sec sec-type="appendix" id="s8-1"><title>Colorado Clinical Center</title><p>Marian Rewers, M.D., Ph.D., PI<sup>1,4,6,9,10</sup>, Kimberly Bautista<sup>11</sup>, Judith Baxter<sup>8,911</sup>, Daniel Felipe-Morales, Brigitte I. Frohnert, M.D., Ph.D.<sup>2,13</sup>, Marisa Stahl, M.D.<sup>12</sup>, Isabel Flores Garcia, Patricia Gesualdo<sup>2,6,11,13</sup>, Sierra Hays, Michelle Hoffman<sup>11,12,13</sup>, Rachel Karban<sup>11</sup>, Edwin Liu, M.D.<sup>12</sup>, Leila Loaiza Jill Norris, Ph.D.<sup>2,3,11</sup>, Holly O’Donnell, Ph.D.<sup>8</sup>, Loana Thorndahl, Andrea Steck, M.D.<sup>3,13</sup>, Kathleen Waugh<sup>6,7,11</sup></p><p>University of Colorado, Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes, Aurora, CO, United States.</p></sec><sec sec-type="appendix" id="s8-2"><title>Finland Clinical Center</title><p>Jorma Toppari, M.D., Ph.D., PI<sup>¥^1,4,10,13</sup>, Olli G. Simell, M.D., Ph.D., Annika Adamsson, Ph.D.<sup>^11</sup>, Suvi Ahonen*<sup>±§</sup>, Mari Åkerlund*<sup>±§</sup>, Sirpa Anttila<sup>µ¤</sup>, Leena Hakola*<sup>±</sup>, Anne Hekkala, M.D.<sup>µ¤</sup>, Tiia Honkanen<sup>µ¤</sup>, Heikki Hyöty, M.D., Ph.D.*<sup>±6</sup>, Jorma Ilonen, M.D., Ph.D.<sup>¥3</sup>, Sanna Jokipuu<sup>^</sup>, Taru Karjalainen<sup>µ¤</sup>, Leena Karlsson<sup>^</sup>, Jukka Kero M.D., Ph.D.<sup>¥^3, 13</sup>, Jaakko J. Koskenniemi M.D., Ph.D.<sup>¥^</sup>, Miia Kähönen<sup>µ¤11,13</sup>, Mikael Knip, M.D., Ph.D.*<sup>±</sup>, Minna-Liisa Koivikko<sup>µ¤</sup>, Katja Kokkonen*<sup>±</sup>, Merja Koskinen*<sup>±</sup>, Mirva Koreasalo*<sup>±§2</sup>, Kalle Kurppa, M.D., Ph.D.*<sup>±12</sup>, Salla Kuusela, M.D. <sup>µ¤</sup>, Jarita Kytölä<sup>*±</sup>, Jutta Laiho, Ph.D.*<sup>6</sup>, Tiina Latva-aho<sup>µ¤</sup>, Siiri Leisku<sup>*±</sup>, Laura Leppänen<sup>^</sup>, Katri Lindfors, Ph.D.*<sup>12</sup>, Maria Lönnrot, M.D., Ph.D.*<sup>±6</sup>, Elina Mäntymäki<sup>^</sup>, Markus Mattila*<sup>±</sup>, Maija Miettinen<sup>§2</sup>, Teija Mykkänen<sup>µ¤</sup>, Tiina Niininen<sup>±</sup>*<sup>11</sup>, Sari Niinistö<sup>§2</sup>, Noora Nurminen<sup>*±</sup>, Sami Oikarinen, Ph.D.*<sup>±6</sup>, Hanna-Leena Oinas*<sup>±</sup>, Paula Ollikainen<sup>µ¤</sup>, Zhian Othmani<sup>¥</sup>, Sirpa Pohjola <sup>µ¤</sup>, Solja Raja-Hanhela<sup>µ¤</sup>, Jenna Rautanen<sup>±§</sup>, Anne Riikonen*<sup>±§2</sup>, Minna Romo<sup>^</sup>, Juulia Rönkä<sup>µ¤</sup>, Nelli Rönkä<sup>µ¤</sup>, Satu Simell, M.D., Ph.D.<sup>¥12</sup>, Päivi Tossavainen, M.D.<sup>µ¤</sup>, Mari Vähä-Mäkilä<sup>¥</sup>, Eeva Varjonen<sup>^11</sup>, Riitta Veijola, M.D., Ph.D.<sup>µ¤13</sup>, Irene Viinikangas<sup>µ¤</sup>, Silja Vilmi<sup>µ¤</sup>, Suvi M. Virtanen, M.D., Ph.D.*<sup>±§2</sup>.</p><p><sup>¥</sup>University of Turku, Turku, Finland</p><p>*Tampere University, Tampere, Finland</p><p><sup>µ</sup>University of Oulu, Oulu, Finland</p><p><sup>^</sup>Turku University Hospital, Hospital District of Southwest Finland, Turku, Finland</p><p><sup>±</sup>Tampere University Hospital, Tampere, Finland</p><p><sup>¤</sup>Oulu University Hospital, Oulu, Finland</p><p>§Finnish Institute for Health and Welfare, Helsinki, Finland</p></sec><sec sec-type="appendix" id="s8-3"><title>Georgia/Florida Clinical Center</title><p>Richard McIndoe, Ph.D., PI<sup>^4,10</sup>, Desmond Schatz, M.D.*<sup>4,7,8</sup>, Diane Hopkins<sup>^11</sup>, Michael Haller, M.D.*<sup>13</sup>, Risa Bernard<sup>^11</sup>, Melissa Gardiner<sup>^11</sup>, Ashok Sharma, Ph.D.<sup>^</sup>, Laura Jacobsen, M.D.*<sup>13</sup>, Jennifer Hosford<sup>^</sup>, Kennedy Petty<sup>^</sup>, Leah Myers<sup>^</sup>, Chelsea Salmon*</p><p><sup>^</sup>Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA, United States</p><p>*University of Florida, Pediatric Endocrinology, Gainesville, FL, United States</p></sec><sec sec-type="appendix" id="s8-4"><title>Germany Clinical Center</title><p>Anette G. Ziegler, M.D., PI<sup>1,3,4,10</sup>, Ezio Bonifacio Ph.D.*, Cigdem Gezginci, Willi Grätz, Anja Heublein, Eva Hohoff<sup>¥2</sup>, Sandra Hummel, Ph.D.<sup>2</sup>, Annette Knopff<sup>7</sup>, Melanie Köger, Sibylle Koletzko, M.D.<sup>¶12</sup>, Claudia Ramminger<sup>11</sup>, Roswith Roth, Ph.D.<sup>8</sup>, Jennifer Schmidt, Marlon Scholz, Joanna Stock<sup>8,11,13</sup>, Katharina Warncke, M.D.<sup>13</sup>, Lorena Wendel, Christiane Winkler, Ph.D.<sup>2,11</sup></p><p>Forschergruppe Diabetes e.V. and Institute of Diabetes Research, Helmholtz Zentrum München, Forschergruppe Diabetes, and Klinikum rechts der Isar, Technische Universität München, Neuherberg, Germany</p><p>*Center for Regenerative Therapies, TU Dresden, Dresden, Germany</p><p><sup>¶</sup>Dr. von Hauner Children’s Hospital, Department of Gastroenterology, Ludwig Maximillians University Munich, Munich, Germany</p><p><sup>¥</sup>University of Bonn, Department of Nutritional Epidemiology, Bonn, Germany</p></sec><sec sec-type="appendix" id="s8-5"><title>Sweden Clinical Center</title><p>Åke Lernmark, Ph.D., PI<sup>1,3,4,5,6,8,9,10</sup>, Daniel Agardh, M.D., Ph.D.<sup>6,12</sup>, Carin Andrén Aronsson, Ph.D.<sup>2,11,12</sup>, Rasmus Bennet, Corrado Cilio, Ph.D., M.D.<sup>6</sup>, Susanne Dahlberg, Ulla Fält, Malin Goldman Tsubarah, Emelie Ericson-Hallström, Lina Fransson, Emina Halilovic, Gunilla Holmén, Susanne Hyberg, Berglind Jonsdottir, M.D., Ph.D.<sup>11</sup>, Naghmeh Karimi, Helena Elding Larsson, M.D., Ph.D.<sup>6,13</sup>, Marielle Lindström, Markus Lundgren, M.D., Ph.D.<sup>13</sup>, Marlena Maziarz, Ph.D., Jessica Melin<sup>11</sup>, Caroline Nilsson, Kobra Rahmati, Anita Ramelius, Falastin Salami, Ph.D., Anette Sjöberg, Evelyn Tekum Amboh Carina Törn, Ph.D.<sup>3</sup>, Ulrika Ulvenhag, Terese Wiktorsson, Åsa Wimar<sup>13</sup></p><p>Lund University, Lund, Sweden</p></sec><sec sec-type="appendix" id="s8-6"><title>Washington Clinical Center</title><p>William A. Hagopian, M.D., Ph.D., PI<sup>2,3,4,6,7,10,12,13</sup>, Michael Killian<sup>6,7,11,12</sup>, Claire Cowen Crouch<sup>11,13</sup>, Jennifer Skidmore<sup>2</sup>, Trevor Bender, Megan Llewellyn, Cody McCall, Arlene Meyer, Jocelyn Meyer, Denise Mulenga<sup>11</sup>, Nole Powell, Jared Radtke, Shreya Roy, Preston Tucker</p><p>Pacific Northwest Research Institute, Seattle, WA, United States</p></sec><sec sec-type="appendix" id="s8-7"><title>Pennsylvania Satellite Center</title><p>Dorothy Becker, M.D., Margaret Franciscus, MaryEllen Dalmagro-Elias Smith<sup>2</sup>, Ashi Daftary, M.D., Mary Beth Klein, Chrystal Yates</p><p>Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States</p></sec><sec sec-type="appendix" id="s8-8"><title>Data Coordinating Center</title><p>Jeffrey P. Krischer, Ph.D., PI<sup>1,4,5,9,10</sup>, Rajesh Adusumali, Sarah Austin-Gonzalez, Maryouri Avendano, Sandra Baethke, Brant Burkhardt, Ph.D.<sup>6</sup>, Martha Butterworth<sup>2</sup>, Nicholas Cadigan, Joanna Clasen, Kevin Counts, Laura Gandolfo, Jennifer Garmeson, Veena Gowda, Christina Karges, Shu Liu, Xiang Liu, Ph.D.<sup>2,3,8,13</sup>, Kristian Lynch, Ph.D. <sup>6,8</sup>, Jamie Malloy, Lazarus Mramba, Ph.D.<sup>2</sup>, Cristina McCarthy<sup>11</sup>, Jose Moreno, Hemang M. Parikh, Ph.D.<sup>3,8</sup>, Cassandra Remedios, Chris Shaffer, Susan Smith<sup>11</sup>, Noah Sulman, Ph.D., Roy Tamura, Ph.D.<sup>1,2,11,12,13</sup>, Dena Tewey, Henri Thuma, Michael Toth, Ulla Uusitalo, Ph.D.<sup>2</sup>, Kendra Vehik, Ph.D.<sup>4,5,6,8,13</sup>, Ponni Vijayakandipan, Melissa Wroble, Jimin Yang, Ph.D., R.D.<sup>2</sup>, Kenneth Young, Ph.D</p><p><italic>Past staff: Michael Abbondondolo, Lori Ballard, Rasheedah Brown, David Cuthbertson, Stephen Dankyi, Christopher Eberhard, Steven Fiske, David Hadley, Ph.D., Kathleen Heyman, Belinda Hsiao, Francisco Perez Laras, Hye-Seung Lee, Ph.D., Qian Li, Ph.D., Colleen Maguire, Wendy McLeod, Aubrie Merrell, Steven Meulemans, Ryan Quigley, Laura Smith, Ph.D</italic></p><p>University of South Florida, Tampa, FL, United States</p></sec><sec sec-type="appendix" id="s8-9"><title>Project scientist</title><p>Beena Akolkar, Ph.D.<sup>1,3,4,5,6,7,9,10</sup></p><p>National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, United States</p></sec><sec sec-type="appendix" id="s8-10"><title>Autoantibody Reference Laboratories</title><p>Liping Yu, M.D.<sup>^5</sup>, Dongmei Miao, M.D.<sup>^</sup>, Kathlee Gillespie*<sup>5</sup>, Kyla Chandler*, Ilana Kelland*, Yassin Ben Khoud*, Matthew Randell*</p><p><sup>^</sup>Barbara Davis Center for Childhood Diabetes, University of Colorado Denver</p><p>*Bristol Medical School, University of Bristol, United Kingdom</p></sec><sec sec-type="appendix" id="s8-11"><title>Genetics Laboratory</title><p>Stephen S. Rich, Ph.D.<sup>3</sup>, Wei-Min Chen, Ph.D.<sup>3</sup>, Suna OnengutGumuscu, Ph.D.<sup>3</sup>, Emily Farber, Rebecca Roche Pickin, Ph.D., Jonathan Davis, Jordan Davis, Dan Gallo, Jessica Bonnie, Paul Campolieto</p><p>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, United States</p></sec><sec sec-type="appendix" id="s8-12"><title>HLA Reference Laboratory</title><p>William Hagopian<sup>3</sup>, M.D., Ph.D., Jared Radtke, Preston Tucker</p><p>Pacific Northwest Research Institute, Seattle, WA, United States</p><p><italic>Previously Henry Erlich, Ph.D.<sup>3</sup>, Steven J. Mack, Ph.D., Anna Lisa Fear. Center for Genetics, Children’s Hospital Oakland Research Institute</italic></p></sec><sec sec-type="appendix" id="s8-13"><title>Repository</title><p>Chris Deigan</p><p>NIDDK Biosample Repository at Fisher BioServices, Rockville, MD, United States</p><p>(Previously: Ricky Schrock, Polina Malone, Sandra Ke, Niveen Mulholland, Ph.D.)</p></sec><sec sec-type="appendix" id="s8-14"><title>Other contributors</title><p>Thomas Briese, Ph.D.<sup>6</sup>, Columbia University</p><p>Todd Brusko, Ph.D.<sup>5</sup>, University of Florida, Gainesville, FL, United States</p><p>Teresa Buckner, Ph.D.<sup>2</sup>, University of Northern Colorado, Greeley, CO, United States</p><p>Suzanne Bennett Johnson, Ph.D.<sup>8,11</sup>, Florida State University, Tallahassee, FL, United States</p><p>Eoin McKinney, Ph.D.<sup>5</sup>, University of Cambridge, Cambridge, United Kingdom</p><p>Tomi Pastinen, M.D., Ph.D.<sup>5</sup>, The Children’s Mercy Hospital, Kansas City, MO, United States</p><p>Steffen Ullitz Thorsen, M.D., Ph.D.<sup>2</sup>, Department of Clinical Immunology, University of Copenhagen, Copenhagen, Denmark, and Department of Pediatrics and Adolescents, Copenhagen University Hospital, Herlev, Denmark</p><p>Eric Triplett, Ph.D.<sup>6</sup>,University of Florida, Gainesville, FL, United States</p></sec><sec sec-type="appendix" id="s8-15"><title>Committees</title><p>[1]Ancillary Studies, <sup>2</sup>Diet, <sup>3</sup>Genetics, <sup>4</sup>Human Subjects/Publicity/Publications, <sup>5</sup>Immune Markers, <sup>6</sup>Infectious Agents, <sup>7</sup>Laboratory Implementation, <sup>8</sup>Psychosocial, <sup>9</sup>Quality Assurance, <sup>10</sup>Steering, <sup>11</sup>Study Coordinators, <sup>12</sup>Celiac Disease, <sup>13</sup>Clinical Implementation.</p></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89068.2.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>The University of Melbourne</institution><country>Australia</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study presents <bold>valuable</bold> findings on genetic risk factors for type 1 diabetes and celiac disease using a large cohort from the Environmental Determinants of Diabetes in the Young (TEDDY) study. The evidence supporting the claims of the authors is <bold>solid</bold>, although the inclusion of the genetic effect of this locus on individuals with different genetic backgrounds would have strengthened the study. The work will be of interest to population geneticists working on diabetes and celiac disease.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89068.2.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Polymorphisms in genes in the human leukocyte antigen (HLA) class II region comprise the most important inherited risk factors for many autoimmune diseases including type 1 diabetes (T1D) and celiac disease (CD). The paper focuses on the novel triad ((SNPs): rs3135394, rs9268645, and rs3129877) finding quite interesting results. The paper suggests further studies at the molecular and structural level to increase our fundamental knowledge of the etiology of autoimmune deceases.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89068.2.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this manuscript, Aydemir et al. utilized the large TEDDY study and examined the effect of previously identified tri-SNP in the HLA-DRA gene on the risk of type 1 diabetes (T1D) and celiac disease (CD). They confirmed the protective effect of the tri-SNP haplotype &quot;101&quot; on T1D development. Meanwhile, the same haplotype appeared to be positively associated with risk for CD and the development of CD autoimmunity. The authors further explored the molecular effect of different tri-SNP haplotypes. They proposed that C4A and C4B might be the downstream target.</p><p>Overall, the study is rigorously conducted with proper statistical methods applied. The tri-SNP could be used as an additional risk factor when estimating T1D and celiac disease susceptibility in genetic screening. However, how this locus be incorporated into the current scheme of genetic screening is not discussed and is unlikely to be straightforward.</p></body></sub-article></article>